Enzyme compositions comprising protease, mannanase, and / or cellulase

Abstract

In the present invention new enzyme compositions are provided. More specifically, the present invention provides enzyme compositions comprising at least two enzymes selected from the group consisting of protease, mannanase, and cellulase and methods of making and using these enzymes compositions.

Description

[0001] Enzyme compositions comprising protease, mannanase, and / or cellulase

[0002] Field of the invention

[0003] In the present invention new enzyme compositions are provided. More specifically, the present invention provides enzyme compositions comprising at least two enzymes selected from the group consisting of protease, mannanase, and cellulase and methods of making and using these enzymes compositions.

[0004] Background of the invention

[0005] Enzymes are increasingly used in various application as sustainable alternative to petrochemistry. Enzymes are biodegradable and can be catalytically active already at lower temperatures, which results in reduction of energy consumption. In particular, in the detergent industry enzymes are implemented in washing formulations to improve cleaning efficiency and to reduce energy consumption in a washing step.

[0006] Most typically used enzymes in detergents are proteases and amylases, whereas mannanases and cellulases are used less frequently. Proteases, amylases, mannanases, and cellulases are all hydrolases that differ in the substrate that they can degrade. Proteases degrade proteins, amylases degrade starch, mannanases degrade galactomannan, and cellulases degrade cellulose.

[0007] However, successful cleaning often depends on the effectiveness of removing stains comprised of different types of soils. Thus, successful cleaning depends on the effective removal of stains comprising a complex mixture of protein, starch, galactomannan, cellulose, and other types of partially undefined soiling. The inventors of the present application identified combinations of specific enzymes particularly suitable to be used for the removal of such complex stains.

[0008] Brief summary of the invention

[0009] The present invention is directed to a composition comprising two or more enzymes selected from a different enzyme class (also called “enzyme blend” herein). Specifically, the present invention is directed to a composition comprising at least two enzymes selected from the group consisting of protease, mannanase, and cellulase. The present invention is also directed to a method of making the enzyme composition. Using the composition of specific enzymes of the present invention provides a beneficial cleaning effect when cleaning an object. Thus, the present invention is also directed to the use of the enzyme composition for cleaning an object and to a detergent composition comprising the enzyme composition.

[0010] Detailed description of the invention

[0011] The present invention may be understood more readily by reference to the following detailed description of the embodiments of the invention and the examples included herein.

[0012] Although the present invention will be described with respect to particular embodiments, this description is not to be construed in a limiting sense.

[0013] Definitions

[0014] Unless otherwise noted, the terms used herein are to be understood according to conventional usage by those of ordinary skill in the relevant art.

[0015] Before describing in detail exemplary embodiments of the present invention, definitions important for understanding the present invention are given. Unless stated otherwise or apparent from the nature of the definition, the definitions apply to all compounds, methods and uses described herein.

[0016] As used in this specification and in the appended claims, the singular forms of "a" and "an" also include the respective plurals unless the context clearly dictates otherwise.

[0017] In the context of the present invention, the terms "about" and "approximately" denote an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±20 %, preferably ±15 %, more preferably ±10 %, and even more preferably ±5 %. Furthermore, the terms "first", "second", "third" or "(a)", "(b)", "(c)", "(d)" etc. and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein. In case the terms "first", "second", "third" or "(a)", "(b)", "(c)", "(d)", "i", "ii" etc. relate to steps of a method or use or assay there is no time or time interval coherence between the steps, i.e. the steps may be carried out simultaneously or there may be time intervals of seconds, minutes, hours, days, weeks, months or even years between such steps, unless otherwise indicated in the application as set forth herein above or below.

[0018] Throughout this application, various publications are referenced. The disclosures of all of these publications and those references cited within those publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

[0019] It is to be understood that the term "comprising" is not limiting. For the purposes of the present invention the term "consisting of" is considered to be a preferred embodiment of the term "comprising". If hereinafter a group is defined to comprise at least a certain number of members, this is meant to also encompass a group which consists of these members only.

[0020] “Variant” enzymes differ from “parent” enzymes by certain amino acid alternations, preferably amino acid substitutions at one or more amino acid positions.

[0021] In describing the variants of the present invention, the abbreviations for single amino acids are used according to the accepted IUPAC single letter or three letter amino acid abbreviation. “Amino acid alteration” as used herein refers to amino acid substitution, deletion, or insertion. “Substitutions” are described by providing the original amino acid followed by the number of the position within the amino acid sequence, followed by the amino acid, which substitutes the original amino acid. For example, the substitution of histidine at position 120 with alanine is designated as “His120Ala” or “H120A”. Substitutions can also be described by merely naming the resulting amino acid in the variant without specifying the amino acid of the parent at this position, e.g., “X120A” or “120A” or “Xaa120Ala” or “120Ala”.

[0022] “Deletions” are described by providing the original amino acid followed by the number of the position within the amino acid sequence, followed by *. Accordingly, the deletion of glycine at position 150 is designated as “Gly150*” or G150*”. Alternatively, deletions are indicated by, e.g., “deletion of D183 and G184”.

[0023] “Insertions” are described by providing the original amino acid followed by the number of the position within the amino acid sequence, followed by the original amino acid and the additional amino acid. For example, an insertion at position 180 of lysine next to glycine is designated as “Gly180GlyLys” or “G180GK”. When more than one amino acid residue is inserted, such as, e.g., a Lys and an Ala after Gly180 this may be indicated as: “Gly180GlyLysAla” or “G195GKA”. In cases where a substitution and an insertion occur at the same position, this may be indicated as “S99SD+S99A” or in short “S99AD”. Variants comprising multiple alterations are separated representing a substitution of arginine and glycine at positions 170 and 195 with tyrosine and glutamic acid, respectively. Alternatively, multiple alterations may be separated by space or a comma, e.g., “R170Y G195E” or “R170Y, G195E” respectively. Where different alternative alterations can be introduced at a position, the different alterations are separated by a comma, e.g., “Arg170Tyr, Glu” and “R170T, E”, respectively, represents a substitution of arginine at position 170 with tyrosine or glutamic acid. Alternative substitutions at a particular position can also be indicated as “X120A,G,H”, “120A.G.H”, “X120A / G / H”, or “120A / G / H”. Alternatively, different alterations or optional substitutions may be indicated in brackets, e.g., “Arg170[Tyr, Gly]” or “Arg170{Tyr, Gly}” or in short “R170 [Y, GJ” or “R170 {Y, G}”.

[0024] The term “native” (or naturally or wildtype or endogenous) cell or organism or polynucleotide or polypeptide refers to the cell or organism or polynucleotide or polypeptide as found in nature (i.e. , without there being any human intervention).

[0025] The term “introduction of at least two negative charges” into a particular amino acid sequence refers to the increase of the net charge of the particular amino acid sequence by at least two negative charges. Such increase of the net charge of the particular amino acid sequence by at least two negative charges is achieved by altering the amino acid sequence and can be reached by one or more amino acid sequence alterations selected from the group consisting of substitution, deletion and insertion, preferably by one or more amino acid substitutions. The increase of the net charge of the particular amino acid sequence by at least two negative charges can be achieved by removing positive charges or by introducing negative charges or by combinations thereof. The four amino acids aspartic acid (Asp, D), glutamic acid (Glu, E), lysine (Lys, K), and arginine (Arg, R) have a side chain which can be charged at neutral pH. At pH 7.0, two are negatively charged: aspartic acid (Asp, D) and glutamic acid (Glu, E) (acidic side chains), and two are positively charged: lysine (Lys, K) and arginine (Arg, R) (basic side chains). Thus, the introduction of at least two negative charges in the amino acid sequence can be reached for instance by substituting arginine by glutamic acid, substituting two non-charged leucine residues by two glutamic acid residues, by inserting two aspartic acid residues or by deleting two lysine residues. The introduction of at least two negative charges by modification of the amino acid sequence is evaluated preferably under conditions usually occurring in a washing step, preferably at pH 6-11 , preferably at pH 7-9, more preferably at pH 7.5-8.5, further preferred at pH 7.0-8.0, most preferably at pH 7.0 or pH 8.0. The term "heterologous” (or exogenous or foreign or recombinant or non-native or non-naturally) polypeptide is defined herein as a polypeptide that is not native to the host cell, a polypeptide native to the host cell in which structural modifications, e.g., deletions, substitutions, and / or insertions, have been made by recombinant DNA techniques to alter the native polypeptide, or a polypeptide native to the host cell whose expression is quantitatively altered or whose expression is directed from a genomic location different from the native host cell as a result of manipulation of the DNA of the host cell by recombinant DNA techniques, e.g., a stronger promoter.

[0026] Similarly, the term “heterologous” (or exogenous or foreign or recombinant or non-native or non- naturally) polynucleotide refers to a polynucleotide that is not native to the host cell, a polynucleotide native to the host cell in which structural modifications, e.g., deletions, substitutions, and / or insertions, have been made by recombinant DNA techniques to alter the native polynucleotide, or a polynucleotide native to the host cell whose expression is quantitatively altered as a result of manipulation of the regulatory elements of the polynucleotide by recombinant DNA techniques, e.g., a stronger promoter, or a polynucleotide native to the host cell, but integrated not within its natural genetic environment as a result of genetic manipulation by recombinant DNA techniques. With respect to the relation between two or more polynucleotide sequences or the relation between two or more amino acid sequences, the term "heterologous” is used to characterize that the two or more polynucleotide sequences or two or more amino acid sequences are naturally not occurring in the specific combination with each other.

[0027] For the purpose of the invention, "recombinant" (or transgenic) with regards to a cell or an organism means that the cell or organism contains a heterologous polynucleotide, which is introduced by man using gene technology. With regards to a polynucleotide “recombinant” includes all constructs produced by using gene technology I recombinant DNA techniques in which either

[0028] (a) the sequence of the polynucleotide or a part thereof, or

[0029] (b) one or more genetic control sequences, which are operably linked to the polynucleotide, including but not limited to a promoter, or

[0030] (c) both a) and b) are not located in their wildtype genetic environment or have been modified by man. A "synthetic" compound is obtained by in vitro chemical and / or enzymatic synthesis.

[0031] Variant polynucleotide and variant polypeptide sequences may be defined by their sequence identity when compared to another sequence. Sequence identity usually is provided as “% sequence identity” or “% identity”. For calculation of sequence identities, in a first step a sequence alignment is produced. According to this invention, a pairwise global alignment is produced, meaning that two sequences are aligned over their complete length, which is usually produced by using a mathematical approach, called alignment algorithm.

[0032] According to the invention, the alignment is generated by using the algorithm of Needleman and Wunsch (J. Mol. Biol. (1979) 48, p. 443-453). Preferably, the program “NEEDLE” (The European Molecular Biology Open Software Suite (EMBOSS)) is used for the purposes of the current invention, with using the programs default parameter (polynucleotides: gap open=10.0, gap extend=0.5 and matrix=EDNAFULL; polypeptides: gap open=10.0, gap extend=0.5 and ma- trix=EBLOSUM62). After aligning two sequences, in a second step, an identity value is determined from the alignment produced. For this purpose, the %-identity is calculated by dividing the number of identical residues by the length of the alignment region which is showing the respective sequence of the present invention over its complete length multiplied with 100: %-identity = (identical residues I length of the alignment region which is showing the respective sequence of the present invention over its complete length) *100.

[0033] For calculating the percent identity of two nucleic acid sequences the same applies as for the calculation of percent identity of two amino acid sequences with some specifications. For nucleic acid sequences encoding for a protein the pairwise alignment shall be made over the complete length of the coding region of the sequence of this invention from start to stop codon excluding introns. Introns present in the other sequence, to which the sequence of this invention is compared, shall also be removed for the pairwise alignment. After aligning two sequences, in a second step, an identity value is determined from the alignment produced. Percent identity is calculated by %-identity = (identical residues I length of the alignment region which is showing the sequence of the invention from start to stop codon excluding introns over its complete length) *100.

[0034] Moreover, the preferred alignment program for nucleic acid sequences implementing the Needleman and Wunsch algorithm (J. Mol. Biol. (1979) 48, p. 443-453) is “NEEDLE” (The European Molecular Biology Open Software Suite (EMBOSS)) with the programs default parameters (gapopen=10.0, gapextend=0.5 and matrix=EDNAFULL).

[0035] Variant polypeptides may also be defined by their sequence similarity when compared to another sequence. Sequence similarity usually is provided as “% sequence similarity” or “%-similarity”. % sequence similarity takes into account that defined sets of amino acids share similar properties, e.g. by their size, by their hydrophobicity, by their charge, or by other characteristics. Herein, the exchange of one amino acid with a similar amino acid may be called “conservative mutation”. Similar amino acids according to the invention are defined as follows, which shall also apply for determination of %-similarity according to this invention, which is also in accordance with the BLOSUM62 matrix as for example used by program “NEEDLE”, which is one of the most used amino acids similarity matrix for database searching and sequence alignments:

[0036] Amino acid A is similar to amino acids S

[0037] Amino acid D is similar to amino acids E; N

[0038] Amino acid E is similar to amino acids D; K; Q

[0039] Amino acid F is similar to amino acids W; Y

[0040] Amino acid H is similar to amino acids N; Y

[0041] Amino acid I is similar to amino acids L; M; V

[0042] Amino acid K is similar to amino acids E; Q; R

[0043] Amino acid L is similar to amino acids I; M; V

[0044] Amino acid M is similar to amino acids I; L; V

[0045] Amino acid N is similar to amino acids D; H; S

[0046] Amino acid Q is similar to amino acids E; K; R

[0047] Amino acid R is similar to amino acids K; Q

[0048] Amino acid S is similar to amino acids A; N; T

[0049] Amino acid T is similar to amino acids S

[0050] Amino acid V is similar to amino acids I; L; M

[0051] Amino acid W is similar to amino acids F; Y

[0052] Amino acid Y is similar to amino acids F; H; W

[0053] For calculation of sequence similarity, in a first step a sequence alignment is produced as de- scribed above. After aligning two sequences, in a second step, a similarity value is determined from the alignment produced. For this purpose, the %-similarity is calculated by dividing the number of identical residues plus the number of similar residues by the length of the alignment region which is showing the sequence of the invention over its complete length multiplied with 100: Cosimilarity = [(identical residues + similar residues) I length of the alignment region which is show- ing the sequence of the invention over its complete length] *100.

[0054] A "fragment" or “subsequence” as used herein is a portion of a polynucleotide or an amino acid sequence. The term “functional fragment” refers to any nucleic acid or amino acid sequence which comprises merely a part of the full-length amino acid sequence, respectively, but still has the same or similar activity and / or function. Preferably, the functional fragment is at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80% identical, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98.5 %, at least 99%, or at least 99.5% identical to the original full length amino acid sequence. The functional fragment comprises consecutive nucleotides or amino acids compared to the original nucleic acid or original amino acid sequence, respectively.

[0055] “Genetic construct” or “expression cassette” as used herein, is a nucleic acid molecule composed of at least one sequence of interest to be expressed, operably linked to one or more control sequences (at least to a promoter) as described herein.

[0056] The term “vector” as used herein comprises any kind of construct suitable to carry foreign polynucleotide sequences for transfer to another cell, or for stable or transient expression within a given cell. The term “vector” as used herein encompasses any kind of cloning vehicles, such as but not limited to plasmids, phagemids, viral vectors (e.g., phages), bacteriophage, baculoviruses, cosmids, fosmids, artificial chromosomes, and any other vectors specific for specific hosts of interest. Foreign polynucleotide sequences usually comprise a coding sequence which may be referred to herein as “gene of interest”. The gene of interest may comprise introns and exons, depending on the kind of origin or destination of host cell.

[0057] The term “introduction of a polynucleotide” or “transformation of a polynucleotide” as referred to herein encompasses the transfer of an exogenous polynucleotide into a host cell, irrespective of the method used for transfer. That is, the term “transformation of a polynucleotide” as used herein is independent from vector, shuttle system, or host cell, and it not only relates to the polynucleotide transfer method of transformation as known in the art (cf., for example, Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY), but it encompasses any further kind polynucleotide transfer methods such as, but not limited to, transduction or transfection.

[0058] A polynucleotide encoding a polypeptide may be “expressed”. The term “expression” or “gene expression” means the transcription of a gene or genes or genetic construct into structural RNA (e.g., rRNA, tRNA) or mRNA with or without subsequent translation of the latter into a protein. The process includes transcription of DNA and processing of the resulting mRNA product.

[0059] The term “purification” or “purifying” refers to a process in which at least one component, e.g., a protein of interest, is separated from at least another component, e.g., a particulate matter of a fermentation broth, and transferred into a different compartment or phase, wherein the different compartments or phases do not necessarily need to be separated by a physical barrier. Examples of such different compartments are two compartments separated by a filtration membrane or cloth, i.e. , filtrate and retentate; examples of such different phases are pellet and supernatant or cake and filtrate, respectively. The resulting solution after purifying the enzyme of interest from the fermentation broth is called herein “purified enzyme solution”.

[0060] “Protein formulation” (or “enzyme preparation”), e.g., “protein variant formulation”, means any non-complex formulation comprising a small number of ingredients, wherein the ingredients serve the purpose of stabilizing the proteins comprised in the protein formulation and / or the stabilization of the protein formulation itself. Preferably, the non-complex protein formulation comprises the protein in higher concentrations than the complex formulation, e.g., than a detergent composition. Thus, preferably the non-complex protein formulation is a concentrated protein variant formulation. Preferably, non-complex protein formulations comprise 2 to 120 mg / g active enzyme, wherein complex formulations, like detergent compositions, comprise 0.002 to 6 mg / g active enzyme.

[0061] “Enzyme properties” include, but are not limited to catalytic activity, substrate / cofactor specificity, product specificity, stability in the course of time, thermostability, pH stability, and chemical stability. “Enzymatic activity” or “catalytic activity” means the catalytic effect exerted by an enzyme, expressed as units per milligram of enzyme (specific activity) or molecules of substrate transformed per minute per molecule of enzyme (molecular activity). Enzymatic activity can be specified by the enzymes actual function, e.g., proteases exerting proteolytic activity by catalyzing hydrolytic cleavage of peptide bonds, lipases exerting lipolytic activity by hydrolytic cleavage of ester bonds, amylases activity involves hydrolysis of glycosidic linkages in polysaccharides, etc.

[0062] The term “enzyme stability” according to the current invention relates to the retention of enzymatic activity as a function of time during storage or operation. Retention of enzymatic activity as a function of time during storage is called “storage stability” and is preferred within the context of the invention.

[0063] To determine and quantify changes in catalytic activity of enzymes stored or used under certain conditions over time, the “initial enzymatic activity” is measured under defined conditions at time zero (100%) and at a certain point in time later (x%). By comparison of the values measured, a potential loss of enzymatic activity can be determined in its extent. The extent of enzymatic activity loss determines an enzyme’s stability or non-stability as such or in a formulation.

[0064] “Enzyme inhibitors” as used herein are compounds that slow down or halt enzymatic activity. Enzyme inhibitors frequently also stabilize the enzyme in its three-dimensional structure. Hence, enzyme inhibitors usually also act as “enzyme stabilizers”. “pH stability” refers to the ability of an enzyme to exert enzymatic activity after exposure to certain pH value.

[0065] The terms “thermal stability”, “thermostability” or “temperature-dependent activity” refer to the ability of an enzyme to exert catalytic activity or wash performance after exposure to elevated temperatures, preferably at a temperature of 40 °C for 28 days, more preferably 56 days, preferably in a detergent composition (preferably, in model ES1 -C detergent), or at 92 °C for at least 10 min.

[0066] The terms “detergent stability” or “stability under storage in a detergent composition” refer to the ability of an enzyme to exert catalytic activity or wash performance after storage in a detergent composition, preferably at a temperature of 40 °C or 50 °C for 28 days, more preferably 56 days, in a detergent composition (preferably, in model ES1 -C detergent).

[0067] As used herein, "wash performance" (also called herein “cleaning performance”) of an enzyme refers to the contribution of the enzyme to the cleaning performance of a detergent composition, i.e. the cleaning performance added to the detergent composition by the performance of the enzyme. The term “wash performance” is used herein similarly for laundry and hard surface cleaning. Wash performance is compared under relevant washing conditions. The term "relevant washing conditions" is used herein to indicate the conditions, particularly washing temperature, time, washing mechanics, sud concentration, type of detergent and water hardness, actually used in households in a detergent market segment. The term "improved wash performance" is used to indicate that a better end result is obtained in stain removal under relevant washing conditions, or that less enzyme, on weight basis, is needed to obtain the same end result relative to the corresponding control conditions.

[0068] As used herein, the term "specific performance" refers to the cleaning and removal of specific stains or soils per unit of active enzyme. In some embodiments, the specific performance is determined using stains or soils such as egg, egg yolk, milk, grass, minced meat, blood, chocolate sauce, baby food, sebum, etc.

[0069] “Detergent composition”, “detergent formulation”, or “detergent” means compositions designated for cleaning soiled material. Detergent compositions according to the invention include detergent compositions for different applications such as laundry and hard surface cleaning. The term “detergent component” is defined herein to mean a type of chemical, which can be used in detergent compositions. A typical detergent component is a surfactant. "Surfactant" (synonymously used herein with “surface active agent”) means an organic chemical that, when added to a liquid, changes the properties of that liquid at an interface. According to its ionic charge, a surfactant is called non-ionic, anionic, cationic, or amphoteric. The term “effective amount of a detergent component” includes amounts of certain components to provide effective stain removal and / or effective cleaning conditions (e.g. pH, temperature, water hardness), amounts of certain components to effectively provide optical benefits (e.g. optical brightening, dye transfer inhibition, color care), and amounts of certain components to effectively aid the processing (maintain physical characteristics during processing, storage and use; e.g. rheology modifiers, hydrotropes, desiccants). The term “laundry” or “laundering” relates to both household laundering and industrial laundering and means the process of treating textiles and / or fabrics with a solution containing a detergent composition of the present invention. The laundering process may be carried out by using technical devices such as a household or an industrial washing machine. Alternatively, the laundering process may be done by hand.

[0070] The term “textile” means any textile material including yarns (thread made of natural or synthetic fibers used for knitting or weaving), yarn intermediates, fibers, non-woven materials, natural materials, synthetic materials, as well as fabrics made of these materials such as garments, cloths and other articles. The terms “fabric” (a textile made by weaving, knitting or felting fibers) or “garment” (any article of clothing made of textile) as used herein, mean to include the broader term textile as well.

[0071] The term “fibers” includes natural fibers, synthetic fibers, and mixtures thereof. Examples of natural fibers are of plant (such as flax, jute and cotton) or animal origin, comprising proteins like collagen, keratin and fibroin (e.g. silk, sheep wool, angora, mohair, cashmere). Examples for fibers of synthetic origin are polyurethane fibers such as Spandex® or Lycra®, polyester fibers, polyolefins such as elastofin, or polyamide fibers such as nylon. Fibers may be single fibers or parts of textiles such as knitwear, woven or non-woven fabrics.

[0072] The term “hard surface cleaning” relates to both household hard surface cleaning and industrial hard surface cleaning and means the process of treating hard surfaces with a solution containing a detergent composition of the present invention. Hard surfaces may include any hard surfaces in the household or industry, such as floors, furnishing, walls, sanitary ceramics, glass, metallic surfaces including medical devices, cutlery, and dishes. A particular form of hard surface cleaning is dishwashing, manual dish washing (MDW) or automatic dishwashing (ADW). The term “dish wash” refers to all forms of washing dishes, e.g. by hand or automatic dish wash. Washing dishes includes, but is not limited to, the cleaning of all forms of crockery such as plates, cups, glasses, bowls, all forms of cutlery such as spoons, knives, forks and serving utensils as well as ceramics, plastics such as melamine, metals, china, glass and acrylics. Cleaning performance is evaluated under relevant cleaning conditions. The term "relevant cleaning conditions" herein refers to the conditions, particularly cleaning temperature, time, cleaning mechanics, suds concentration, type of detergent and water hardness, actually used in laundry machines, automatic dish washers or in manual cleaning processes.

[0073] The term “medical device cleaning” refers to the cleaning step in reprocessing reusable medical devices. Medical device cleaning methods can be divided into two categories, manual and me- chanical / automated cleaning methods. Manual cleaning is used when mechanical units are not available or medical devices to be cleaned are too fragile or difficult to clean with a mechanical unit. Mechanical / automated cleaning methods remove soiling and microorganisms through an automated cleaning and rinsing process, this includes ultrasonic cleaning and washing.

[0074] In the field of detergency, usually the term “stains” is used with reference to laundry, e.g., cleaning for textiles, fabric, or fibers, whereas the term “soils” is usually used with reference to hard surface cleaning, e.g., cleaning of dishes and cutlery. However, herein the terms “stain” and “soil” are used interchangeably.

[0075] A “sequestering builder” as used herein is different from a precipitating builder in that no significant amount of precipitate is formed when the builder is used in an amount sufficient to combine with all of the calcium ions in an aqueous solution with 7 °dH hardness (German hardness) initially at neutral pH. A “strong builder” is classified as high efficiency chelator that can bind divalent cations such as Ca2+ strongly with a logarithmic stability constant (Log KCa) of the cat- ion / chelator complex of above 4, particular above 5, above 6 or above 7. The stability constants are determined at an ionic strength of 0.1 M and at a temperature of 25 °C. A ..strong sequestering builder” combines both of the above-mentioned properties.

[0076] A “complex stain” (also called “mixed stain” herein) is a stain comprising more than one soil component selected from fat, protein, starch, mannan, cellulose, preferably wherein the stain comprises a thickening agent like galactomannan or locust bean gum. An example of a complex stain is a salad dressing stain. Further food stains, like chocolate pudding or baby food, are considered to be complex stains.

[0077] The term “synergy” or “synergistic effect” as used herein refers to the interaction of two or more enzymes to produce a combined effect, e.g., wash performance, greater than the sum of their separate effects.

[0078] The term “low temperature” as used herein refers to a temperature range equal or below 40 °C, preferably 10-40 °C, more preferably 20-40 °C, more preferably 20-35 °C. Detailed

[0079] In the present invention new enzyme compositions are provided. More specifically, the present invention provides enzyme compositions comprising two or more enzymes selected from the group consisting of protease, mannanase, and cellulase and methods of making and using these enzymes compositions.

[0080] Particularly, the present inventors found that using in such enzyme compositions at least one enzyme selected from aa. a protease variant of a parent protease, wherein the protease variant comprises

[0081] (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0082] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 16-34, preferably SEQ ID NO: 16, bb. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0083] (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and

[0084] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and cc. a cellulase comprising amino acid sequence which is at least 60% identical to SEQ ID NO: 42, provides a beneficial cleaning effect.

[0085] In one embodiment, the present invention is directed to an enzyme composition.

[0086] In particular, the present invention is directed to a composition comprising two or more enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is selected from

[0087] I. a protease variant of a parent protease, wherein the protease variant comprises (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0088] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to any of SEQ ID NO: 16-34, preferably SEQ ID NO: 16, or

[0089] II. a protease variant of a parent protease, wherein the protease variant comprises

[0090] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 3, 4, 9, 19, 22, 43, 62, 63, 76, 87, 99, 101 , 103, 104, 116, 118, 128, 129, 130, 156, 160, 167, 170, 182, 185, 188, 194, 205, 213, 217, 218, 232, 245, 256, 259, 262, and 271 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 22, or

[0091] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 53, 76, 78, 101 , 128, and 217 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 17, or

[0092] (iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 89, 130, 133, 144, 159, 183, 189. 217, 224, 238, 243, 252, 259, 270 and 271 according to the numbering of SEQ ID NO: 19 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 19, or

[0093] (iv) an amino acid sequence which has at least 60% sequence identity with SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31 , b. the mannanase is selected from

[0094] I. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0095] (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and (ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, or

[0096] II. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0097] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 123, and 256 according to the numbering of SEQ ID NO: 39 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 39, or

[0098] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 10, 19, 30, 38, 59, 60, 67, 97, 103, 129, 143, 167, 168, 184, 225, 228, 235, 244, 258, 261 , and 298 according to the numbering of SEQ ID NO: 38 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 38, or

[0099] (iii) an amino acid sequence which is at least 60% identical to SEQ ID NO: 40, or

[0100] (iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 30, 81 , 93, 95, 118, 138, 139, 200, 202, 210, 260, 283, 288, 294, and 295 according to the numbering of SEQ ID NO: 40 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 40, c. the cellulase is selected from

[0101] I. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 42, or

[0102] II. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 46, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 44, or SEQ ID NO: 47, and wherein at least one enzyme is selected from the group consisting of aa. a protease variant of a parent protease, wherein the protease variant comprises

[0103] (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0104] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 16-34, preferably SEQ ID NO: 16, bb. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0105] (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and

[0106] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and cc. a cellulase comprising amino acid sequence which is at least 60% identical to SEQ ID NO: 42.

[0107] In a preferred embodiment, the present invention is directed to an enzyme composition comprising two or more enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is selected from

[0108] I. a protease variant of a parent protease, wherein the protease variant comprises

[0109] (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0110] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to any of SEQ ID NO: 16-34, preferably SEQ ID NO: 16, b. the mannanase is selected from

[0111] I. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0112] (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and

[0113] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and c. the cellulase is selected from I. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 42.

[0114] In one embodiment, the composition comprises a protease and a mannanase as described herein. In one embodiment, the composition comprises a protease and a cellulase as described herein. In one embodiment, the composition comprises a mannanase and a cellulase as described herein. Preferably, , the composition comprises a protease and a mannanase as described herein. More preferably, the invention is directed to a composition comprising a protease, a mannanase, and a cellulase as described herein. In one embodiment, the composition further comprises an amylase. Thus, in another embodiment the composition comprises a protease, a mannanase, and a cellulase and an amylase as described herein.

[0115] Preferably, the composition comprises a protease and a mannanase, a protease and a cellulase, a mannanase and a cellulase or a protease, a mannanase, and a cellulase, wherein protease, cellulase, and mannanase are selected from aa. a protease variant of a parent protease, wherein the protease variant comprises

[0116] (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0117] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 16-34, preferably SEQ ID NO: 16, bb. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0118] (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and

[0119] (ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and cc. a cellulase comprising amino acid sequence which is at least 60% identical to SEQ ID NO: 42. In one embodiment, the present invention is directed to an enzyme composition comprising two or more enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein the composition comprises two or more different proteases, mannanases, and / or cellulases as described herein, e.g., an anti-greying and an anti-pilling cellulase.

[0120] Proteases

[0121] In one embodiment, the enzyme composition of the present invention comprises a protease. Proteases and protease variants described herein have protease activity (also called “proteolytic activity” herein). This property is related to the hydrolytic activity of a protease (proteolysis, which means hydrolysis of peptide bonds linking amino acids together in a polypeptide chain) on protein containing substrates, e.g. casein, haemoglobin and BSA. Quantitatively, proteolytic activity is related to the rate of degradation of proteins by a protease or proteolytic enzyme in a defined course of time. The methods for analyzing proteolytic activity are well-known in the literature (see e.g. Gupta et al. (2002), Appl. Microbiol. Biotechnol. 60: 381 -395).

[0122] For instance, proteolytic activity can be determined by using Succinyl-Ala-Ala-Pro-Phe-p-ni- troanilide (Suc-AAPF-pNA, short AAPF; see e.g. DelMar et al. (1979), Analytical Biochem 99, 316-320) as substrate. pNA is cleaved from the substrate molecule by proteolytic cleavage, resulting in release of free pNA which has a yellow color that can be quantified by measuring the optical density at 405 nm (OD405).

[0123] The protease of the enzyme composition is selected from

[0124] - a protease variant of a parent protease, wherein the protease variant comprises an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 16-34, preferably SEQ ID NO: 16, or

[0125] - a protease variant of a parent protease, wherein the protease variant comprises

[0126] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 3, 4, 9, 19, 22, 43, 62, 63, 76, 87, 99, 101 , 103, 104, 116, 118, 128, 129, 130, 156, 160, 167, 170, 182, 185, 188, 194, 205, 213, 217, 218, 232, 245, 256, 259, 262, and 271 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which is at least 60%, but less than 100% sequence identity with SEQ ID NO: 22, or (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 53, 76, 78, 101 , 128, and 217 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which is at least 60%, but less than 100% sequence identity with SEQ ID NO: 17, or

[0127] (iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 89, 130, 133, 144, 159, 183, 189. 217, 224, 238, 243, 252, 259, 270 and 271 according to the numbering of SEQ ID NO: 19 and an amino acid sequence which is at least 60%, but less than 100% sequence identity with SEQ ID NO: 19, or

[0128] (iv) an amino acid sequence which is at least 60% sequence identity with SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31.

[0129] Preferably, the protease of the enzyme composition is a protease variant of a parent protease, wherein the protease variant comprises an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 16-34, preferably SEQ ID NO: 16.

[0130] Preferably, the protease is a variant protease of the parent protease which is preferably a subtil- isin protease.

[0131] Preferably, the parent protease for the protease variant is a protease having at least 60% sequence identity to any of SEQ ID NO: 16-34, preferably the parent protease for the protease variant is protease according to any of SEQ ID NO: 16-34. Most preferably the parent protease for the protease variant is protease according to SEQ ID NO: 16.

[0132] Preferably, in this embodiment, the amino acid residue in the parent protease at the above cited positions (i.e. , X) corresponds to the amino acid residue shown in SEQ ID NO: 16 at the respective position according to the numbering of SEQ ID NO: 17.

[0133] The variant protease comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17 (BPN’ numbering, i.e., wherein the positions are numbered by their correspondence to the amino acid sequence of subtilisin BPN’ of B. amyloliquefaciens, established as SEQ ID NO: 17). Preferably, the protease variant comprises as a catalytic triad the amino acids aspartate, histidine and serine, preferably the protease is a subitilisin protease.

[0134] Preferably, the at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17 are obtained by one or more amino acid alterations selected from the group consisting of substitutions, deletions and insertions, preferably by substitutions or insertions, preferably substitutions.

[0135] Preferably, in the protease the at least two additional negative charges compared to SEQ ID NO: 16 in the loop region of residues 98 to 104 are caused by one or more amino acid substitutions at amino acid position according to the numbering of SEQ ID NO: 17 selected from the group consisting of 98, 99, 100, 101 , 102, 103, and 104, preferably at position 101.

[0136] Preferably, the at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17 are obtained by one or more amino acid alterations selected from the group consisting of X99E, X101 D and X101 E, preferably, D99E, R101 D and R101 E.

[0137] In a preferred embodiment, the protease comprises an amino acid sequence which comprises compared to SEQ ID NO: 16 the amino acid substitution R101 E or R101 D according to the numbering of SEQ ID NO: 17. In another embodiment, the at least two additional negative charges compared to SEQ ID NO: 16 in the loop region of residues 98 to 104 are not caused by the amino acid substitution X101 E or X101 D. Most preferred, the protease comprises an amino acid sequence which comprises compared to SEQ ID NO: 16 the amino acid substitution R101 E according to the numbering of SEQ ID NO: 17.

[0138] In a preferred embodiment, the loop sequence 98-104 has compared to SEQ ID NO: 16 two additional negative charges with the following sequence ADGEGAI, ADGDGAI, ADGDGSV, ADGEGSV, AADGSGSV, AADGEGSV, or ASEGEGSV with longer sequences having an insertion in the loop sequence.

[0139] In a further preferred embodiment, the amino acid sequence of the protease comprises compared to SEQ ID NO: 16 alanine at position 103 (103A) and isoleucine at position 104 (1041) according to the numbering of SEQ ID NO: 17, more preferably, 101 R, 1041, and 103A.

[0140] In a further preferred embodiment, the amino acid sequence of the protease compared to SEQ ID NO: 16 does not comprises an additional amino acid residue in the loop region from position 98 to 104 according to the numbering of SEQ ID NO: 17. Preferably, the amino acid sequence of the protease compared to SEQ ID NO: 16 does not comprises an additional amino acid residue between positions 42-43, 51-55, 155-165, 187-189, 217-218, or 218-219 according to the numbering of SEQ ID NO: 17.

[0141] In a preferred embodiment, the protease comprises compared to SEQ ID NO: 16 one or more further substitutions at one or more position selected from the group consisting of 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101 , 102, 103, 104, 106, 118, 120, 123, 128, 129, 130, 131 , 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252, and 274 according the numbering of SEQ ID NO: 17.

[0142] Preferably, the protease further comprises one or more of the amino acid substitutions selected from the group consisting of X3T, X4I, X156D, X205I, and X262E, according to the numbering of SEQ ID NO: 17.

[0143] Preferably, the protease further comprises one or more of the amino acid substitutions selected from the group consisting of S3T, V4I, S156D, V205I, and L262E, according to the numbering of SEQ ID NO: 17.

[0144] Preferably, the protease further comprises one or more, preferably all, of the amino acid substitutions selected from the group consisting of X3T, X4I, and X205I according to the numbering of SEQ ID NO: 17.

[0145] Preferably, the protease further comprises one or more, preferably all, of the amino acid substitutions selected from the group consisting of S156D and L262E according to the numbering of SEQ ID NO: 17.

[0146] Preferably, the protease has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with any of SEQ ID NO: 16-34.

[0147] Preferably, the protease has at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16.

[0148] Preferably, the protease has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ I D NO: 17.

[0149] Preferably, the protease has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17.

[0150] Preferably, the protease has at least 80%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 the amino acid substitution X101 D or X101 E, preferably X101 E, preferably R101 E, according to the numbering of SEQ ID NO: 17.

[0151] Preferably, the protease has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 the amino acid substitution X101 E, preferably R101 E, according to the numbering of SEQ ID NO: 17. Preferably the variant protease comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and wherein the amino acid sequence of the protease comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17 and the protease comprises compared to SEQ ID NO: 16 one or more substitutions at positions according the numbering of SEQ ID NO: 17 selected from the group consisting of 3, 4, 9, 15, 24, 27, 33, 36, 45, 55, 57, 58, 59, 61 , 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101 , 102, 103, 104, 106, 117, 118, 120, 123, 124, 128, 129, 130, 131 , 136, 137, 143, 154, 156, 160, 161 , 163, 167, 170, 171 , 172, 185, 194, 195, 199, 205, 206, 209, 217, 218, 222, 224, 232, 235, 236, 238, 244, 245, 248, 252, 261 , 262, and 274. In another embodiment of the present invention, the protease comprising as described herein an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and wherein the amino acid sequence of the protease comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104, the amino acid substitution X101 E or X101 D, preferably X101 E, according to the numbering of SEQ ID NO: 17, further comprises according to the numbering of SEQ ID NO: 17 at least one of the amino acid residues selected from the group consisting of a. threonine or serine at position 3 (X3T or X3S), b. isoleucine or valine at position 4 (X4I or X4V), c. serine, alanine, threonine or arginine at position 63 (X63S, X63A, X63T or X63R), d. threonine, aspartic acid or glutamic acid at position 156 (X156T, X156D, or X156E), e. serine or proline at position 194 (X194S or X194P), f. serine, valine, or methionine at position 199 (X199S, X199V, or X199M) g. isoleucine or valine at position 205 (X205I or X205V); and h. aspartic acid, glutamic acid, glutamine, glycine at position or leucine at position 217 (X217D, X217E, X217Q, X217G or X217L).

[0152] Preferably, the protease has at least 80%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 the amino acid substitution X101 D or X101 E, preferably X101 E, and one or more of the amino acid substitutions X3T, X4I, and X205I, preferably S3T, V4I, and V205I according to the numbering of SEQ ID NO: 17. Further preferred, the protease has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 the amino acid substitution R101 D or R101 E, preferably R101 E, and the amino acid substitutions S3T, V4I, and V205I according to the numbering of SEQ ID NO: 17.

[0153] In another embodiment, the protease comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and the protease comprises compared to SEQ ID NO: 16 the amino acid substitution X101 E or X101 D, preferably X101 E, and one or more substitutions selected from the group consisting of X156D, X262E, X137H, X3T, X45E,D,Q, X55N, X58W,Y,L, X59D,M,N,T, X61 D,R, X87E, X97S, X98D,E,R, X106A.W, X117E, X120V,D,K,N, X125M, X129D, X136Q, X144W, X161T, X163A.G, X171 L, X172S, X185Q, X199M, X209W, X222Q, X238H, X244T, X261T.D and X262N,Q,D according to the numbering of SEQ ID NO: 17.

[0154] In one embodiment, the protease comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and the protease comprises compared to SEQ ID NO: 16 the amino acid substitution X101 E or X101 D, preferably X101 E, and one, preferably both, of the substitutions selected from the group consisting of X156D and X262E according to the numbering of SEQ ID NO: 17.

[0155] In another embodiment, the protease comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and the protease comprises compared to SEQ ID NO: 16 the amino acid substitution R101 E or R101 D, preferably R101 E, and one or more substitutions selected from the group consisting of S156D, L262E, Q137H, S3T, R45E,D,Q, P55N, T58W,Y,L, Q59D,M,N,T, G61 D,R, S87E, G97S, A98D,E,R, S106A.W, N117E, H120V,D,K,N, S125M, P129D, E136Q, S144W, S161T, S163A.G, Y171 L, A172S, N185Q, V199M, Y209W, M222Q, N238H, V244T, N261T.D and L262N,Q,D according to the numbering of SEQ ID NO: 17.

[0156] In one embodiment, the protease comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and the protease comprises compared to SEQ ID NO: 16 the amino acid substitution R101 E or R101 D, preferably R101 E, and one, preferably both, of the substitutions selected from the group consisting of S156D and L262E according to the numbering of SEQ ID NO:17. Further preferred, the protease has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 the amino acid substitution R101 D or R101 E, preferably R101 E, and the amino acid substitutions S156D and L262E according to the numbering of SEQ ID NO: 17.

[0157] Proteases with substitutions as described above are shown for instance in SEQ ID NO: 28. Thus, in one embodiment the protease variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 28.

[0158] In another embodiment, the protease comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 16 and the protease comprises compared to SEQ ID NO: 16 the amino acid substitutions R101 E and one or more, preferably both, of S156D and L262E, and optionally at least one further mutation selected from I104T, H120D, Q137H, S141 H, R145H and S163G according to the numbering of SEQ ID NO: 17.

[0159] Preferably, the protease has at least 80% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, wherein compared to SEQ ID NO: 16 the protease comprises one or more conservative amino acid exchanges as described herein. Preferably, compared to SEQ ID NO: 16 the protease comprises at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 10, at least 15, at least 20, at least 30 or at least 40 conservative amino acid exchanges.

[0160] Preferably, compared to SEQ ID NO: 16 a protease described herein can comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid exchanges in addition to the modifications resulting in at least two additional negative charges in the loop region of residues 98 to 104, preferably in addition to the substitution X101 D or X101 E, preferably X101 E, and preferably the amino acid substitutions X3T, X4I, and X205I or the amino acid substitutions X156D and X262E the according to the numbering of SEQ ID NO: 17.

[0161] Preferably, the protease has at least 80% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, wherein compared to SEQ ID NO: 16 the remaining difference in amino acid sequence is due to conservative amino acid exchanges as described herein.

[0162] Preferably, the protease is a protease variant comprising the amino acid substitution X101 E and optional the amino acid substitutions X3T, X4I, and X205I or the amino acid substitutions X156D and X262E according to the numbering of SEQ ID NO: 17, and an amino acid sequence which is at least 80%, but less than 100% identical to SEQ ID NO: 16.

[0163] Most preferably, the protease is a protease variant comprising the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and an amino acid sequence which is at least 80%, but less than 100% identical to SEQ ID NO: 16.

[0164] Most preferred is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E according to the numbering of SEQ ID NO: 17, i.e., only one amino acid exchange compared to SEQ ID NO: 16.

[0165] Alternatively preferred is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E and S3T, V4I, and V205I according to the numbering of SEQ ID NO: 17.

[0166] Alternatively preferred is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E and S156D and L262E according to the numbering of SEQ ID NO: 17.

[0167] In one embodiment the protease variant of the enzyme composition comprises

[0168] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 3, 4, 9, 19, 22, 43, 62, 63, 76, 87, 99, 101 , 103, 104, 116, 118, 128, 129, 130, 156, 160, 167, 170, 182, 185, 188, 194, 205, 213, 217, 218, 232, 245, 256, 259, 262, and 271 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO 22, or (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 53, 76, 78, 101 , 128, and 217 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 17, or

[0169] (iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 89, 130, 133, 144, 159, 183, 189. 217, 224, 238, 243, 252, 259, 270 and 271 according to the numbering of SEQ ID NO: 19 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 19, or

[0170] (iv) an amino acid sequence which is at least 60% sequence identity with SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31.

[0171] In one embodiment, the protease variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 22 and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 3, 4, 9, 19, 22, 43, 62, 63, 76, 87, 99, 101 , 103, 104, 116, 118, 128, 129, 130, 156, 160, 167, 170, 182, 185, 188, 194, 205, 213, 217, 218, 232, 245, 256, 259, 262, and 271 according to the numbering of SEQ ID NO: 17.

[0172] Preferably, the protease variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 22 and one or more amino acid substitutions selected from the group consisting of X3T, X4I, X9D / E / R, X19L, X22R / A, X43R, X62D, X63D / E, X76D, X87N, X99A / D, X101 M / R / E, X103A, X104I , X116L, X118V, X128L, X129Q, X130A, X156D / E, X160D / S, X167A, X170S, X182E / D, X185E / D, X188D, X194P, X205I, X213A, X217E / D / Q, X218D, X232V, X245R, X256D / E, X259D / E, X262D / E, and X271 F according to the numbering of SEQ ID NO: 17.

[0173] Preferably, the protease variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 22 and one or more amino acid substitutions selected from the group consisting of S3T, V4I, S9D / E / R, R19L, T22R / A, N43R, N62D, G63D / E, N76D, S87N, S99A / D, S101 M / R / E, S103A, V104I, , N116L, G118V, S128L, P129Q, S130A, S156D / E, G160D / S, Y167A, R170S, Q182E / D, N185E / D, S188D, A194P, V205I, T213A, L217E / D / Q, N218D, A232V, N245R, S256D / E, S259D / E, L262D / E, and E271 F according to the numbering of SEQ ID NO: 17.

[0174] In a preferred embodiment, the protease variant described above further comprises an insertion of D and E directly adjacent C-terminally of the position 99 according to the numbering of SEQ ID NO: 17.

[0175] Proteases with substitutions as described above are shown for instance in SEQ ID NO: 24, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 29.

[0176] Thus, in one embodiment the protease variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to any of SEQ ID NO: 24, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 27, or SEQ ID NO: 29. In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to any of SEQ ID NO: 24, SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 27, or SEQ ID NO: 29.

[0177] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 24.

[0178] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 23.

[0179] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 26.

[0180] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 27.

[0181] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 29.

[0182] In another embodiment, the protease variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 17 and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 53, 76, 78, 101 , 128, and 217 according to the numbering of SEQ ID NO: 17.

[0183] Preferably, the protease variant comprises an amino acid sequence which hasat least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 17 and one or more of the substitutions selected from the group of X24G / R, X53G, X76D, X78N, X101 N, X128A / S, and X217Q / L / E / D according to the numbering of SEQ ID NO: 17.

[0184] Preferably, the protease variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 17 and one or more of the substitutions selected from the group of S24G / R, S53G, N76D, S78N, S101 N, G128A / S, and Y217Q / L / E / D according to the numbering of SEQ ID NO: 17.

[0185] Proteases with substitutions as described above are shown for instance in SEQ ID NO: 32, 33, and 34.

[0186] Thus, in one embodiment the protease variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to any of SEQ ID NO: 32, 33, or 34.

[0187] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 32.

[0188] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 33.

[0189] In one embodiment the protease variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 34.

[0190] In one embodiment the protease variant comprises an amino acid sequence which has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 19 and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 89, 130, 133, 144, 159, 183, 189. 217, 224, 238, 243, 252, 259, 270 and 271 according to the numbering of SEQ ID NO: 19, preferably one or more, preferably all substitutions selected from the group consisting of X159T, X183S, X238N, X243N, X259N and X270A, more preferably one or more, preferably all substitutions selected from the group consisting of X9T, X130D, X133A, X144K, X159T, X183S, X189T, X217M, X224A, X238N, X243N, X252T, X259N, X270A and X271 E, even more preferably one or more, preferably all substitutions selected from the group consisting of X9T, X89A, X130D, X133A, X144K, X159T, X183S, X189T, X217M, X224A, X238N, X243N, X252T, X259N, X270A and X271 E.

[0191] In one embodiment the protease variant comprises an amino acid sequence which has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 19 and one or more, preferably all substitutions selected from the group consisting of X159T, X183S, X238N, X243N, X259N and X270A, more preferably one or more, preferably all substitutions selected from the group consisting of X9T, X130D, X133A, X144K, X159T, X183S, X189T, X217M, X224A, X238N, X243N, X252T, X259N, X270A and X271 E, even more preferably one or more, preferably all substitutions selected from the group consisting of X9T, X89A, X130D, X133A, X144K, X159T, X183S, X189T, X217M, X224A, X238N, X243N, X252T, X259N, X270A and X271 E according to the numbering of SEQ ID NO: 19.

[0192] In one embodiment the protease variant comprises an amino acid sequence which has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 19 and one or more, preferably all substitutions selected from the group consisting of F159T, N183S, Y238N, T243N, D259N and V270A, more preferably one or more, preferably all substitutions selected from the group consisting of P9T, N130D, T133A, N144K, F159T, N183S, S189T, Y217M, S224A, Y238N, T243N, N252T, D259N, V270A and Q271 E, even more preferably one or more, preferably all substitutions selected from the group consisting of P9T, S89A, N130D, T133A, N144K, F159T, N183S, S189T, Y217M, S224A, Y238N, T243N, N252T, D259N, V270A and Q271 E according to the numbering of SEQ ID NO: 19.

[0193] In one embodiment, the protease variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown in SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31.

[0194] Preferably, the protease variant has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown in SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31 .

[0195] Preferably, the protease variant has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown in SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31.

[0196] In one embodiment, the protease according to the present invention preferably has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 22.

[0197] In one embodiment, the protease variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 21.

[0198] In one embodiment, the protease variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 30.

[0199] In one embodiment, the protease variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 20.

[0200] In one embodiment, the protease variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 25.

[0201] In one embodiment, the protease variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 18.

[0202] In one embodiment, the protease according to the present invention preferably has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 19.

[0203] In one embodiment, the protease variant hasat least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 31.

[0204] Mannanases

[0205] In one embodiment, the enzyme composition of the present invention comprises a mannanase. The mannanases and mannanase variants described herein have mannanase activity. “Mannanases” as described herein are enzymes selected from the group of (galacto-)mannan degrading enzyme. The (galacto-)mannan degrading enzyme may be selected from [3-manno- sidases (EC 3.2.1 .25), endo-1 ,4-p-mannosidase (EC 3.2.1 .78), and 1 ,4-p-mannobiosidases (EC 3.2.1.100). Preferably, the mannan degrading enzyme is selected from the group of endo-1 , 4- mannanases, preferably endo-1 ,4-p-mannosidases (EC 3.2.1.78), a group of enzymes which may be called endo-[3-1 ,4-D-mannanase, [3-mannanase, or mannanase herein. Endo-1 , 4-man- nanases randomly hydrolyze the 1 ,4-linkages within the mannan backbone releasing mannooligosaccharides (MOS). The mannanase may be selected from alkaline mannanases of family 5 or 26 (i.e. , GH5 or GH26). The term “alkaline mannanase” is meant to encompass mannanases having an enzymatic activity of at least 40% of their maximum activity at a given pH ranging from 7 to 12, preferably 7.5 to 10.5.

[0206] The mannanase of the enzyme composition is selected from

[0207] - a mannanase variant of a parent mannanase, wherein the mannanase variant comprises one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35 and

[0208] - a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0209] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 123, and 256 according to the numbering of SEQ ID NO: 39 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 39, or

[0210] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 10, 19, 30, 38, 59, 60, 67, 97, 103, 129, 143, 167, 168, 184, 225, 228, 235, 244, 258, 261 , and 298 according to the numbering of SEQ ID NO: 38 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 38, or

[0211] (iii) an amino acid sequence which is at least 60% identical to SEQ ID NO: 40, or

[0212] (iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 30, 81 , 93, 95, 118, 138, 139, 200, 202, 210, 260, 283, 288, 294, and 295 according to the numbering of SEQ ID NO: 40 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 40.

[0213] Preferably, the mannanase of the enzyme composition is a mannanase variant of a parent man- nanase, wherein the mannanase variant comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35.

[0214] Preferably, the mannanase of the enzyme composition is a mannanase variant of a parent man- nanase, wherein the mannanase variant comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and an amino acid sequence which has at least 60%, but less than 100% sequence identity with any of SEQ ID NO: 35-37.

[0215] Preferably, the parent mannanase for the mannanase variant is a mannanase having at least 60% sequence identity to any of SEQ ID NO: 35-37, preferably the parent mannanase for the mannanase variant is mannanase according to any of SEQ ID NO: 35-37. Most preferably the parent mannanase for the mannanase variant is mannanase according to SEQ ID NO: 35. Preferably, in this embodiment, the amino acid residue in the parent protease at the above cited positions (i.e. , X) corresponds to the amino acid residue shown in SEQ ID NO: 35 at the respective position according to the numbering of SEQ ID NO: 35.

[0216] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of X86N, X89V / L, X96D, X101T / V, X103Y / E / A, X107N, X108G, X109Q / A, X112N, X119Y / H / T, X122S, X124E / C / D, X126E, X127A, X129M / L / F, X231Q / K / L / P / Y, X233V, X235H / R / L / Q / N / Y, X244I / V / N, X254W, X255Y / H / R, X264Q / V, X270T, X272I, X273T, X274E / C / Q, X281 L, X286E / L / Q / A, X289F / M / H, X290A, X296H / F / Y, X301 E / C / T, X309L, X312F / Y, X314P, X317T, and X319D / E according to the numbering of SEQ ID NO: 35.

[0217] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of D86N, Q89V / L, N96D, L101T / V, S103Y / E / A, K107N, N108G, N109Q / A, A112N, A119Y / H / T, N122S, A124E / C / D, S126E, S127A, N129M / L / F, S231Q / K / L / P / Y, I233V, S235H / R / L / Q / N / Y, D244I / V / N, H254W, K255Y / H / R, E264Q / V, S270T, Q272I, K273T, N274E / C / Q, S281 L, G286E / L / Q / A, W289F / M / H, S290A, N296H / F / Y, D301 E / C / T, T309L, N312F / Y, A314P, L317T, A319D / E according to the numbering of SEQ ID NO: 35. Preferably, the mannanase further comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 328, 329, 330, 331 , 344, 359, 374, 416, and 432 according to the numbering of SEQ ID NO: 35.

[0218] Preferably, the mannanase variant further comprises one or more amino acid substitution selected from the group consisting of X328I / Q / V, X329L / S / V / T, X330P / D / T, X331A / Q, X344Q / F / T, X359R / Y / C / Q, X374G / V / A / R / N / P, X416W, and X432P / N / L / R / S / T / G / H / I according to the numbering of SEQ ID NO: 35.

[0219] Preferably, the mannanase variant further comprises one or more amino acid substitution selected from the group consisting of D328I / Q / V, G329L / S / V / T, G330P / D / T, D331A / Q, Y344Q / F / T, M359R / Y / C / Q, Y374G / V / A / R / N / P, L416W, and W432P / N / L / R / S / T / G / H / I according to the numbering of SEQ ID NO: 35.

[0220] Preferably, the mannanase variant comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 31 , 89, 96, 119, 264, 289, 312, 348, 349, 352, and 379 according to the numbering of SEQ ID NO: 35.

[0221] Preferably, the mannanase variant comprises amino acid substitutions at position 89 and 96 and an amino acid substitution at one or more amino acid positions selected from the group consisting of 31 , 119, 264, 289, and 312 according to the numbering of SEQ ID NO: 35.

[0222] Preferably, the mannanase variant comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 89, 96, 119, 264, 289, 312, 348, 349, and 352 according to the numbering of SEQ ID NO: 35.

[0223] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of X31V, X89V, X96D, X119Y / H / T, X264Q / V, X289F / M / H, X312F / Y, X348S / R / N / M / G, X349T / S / D / G, X352N / G, and X379V according to the numbering of SEQ ID NO: 35.

[0224] Preferably, the mannanase variant comprises at least one of amino acid substitution X89V and X96D and one or more amino acid substitutions selected from X31 V, X119Y / H / T, X264Q / V, X289F / M / H, and X312F / Y according to the numbering of SEQ ID NO: 35.

[0225] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of A31V, Q89V, N96D, A119Y / H / T, E264Q / V, W289F / M / H, N312F / Y, T348S / R / N / M / G, E349T / S / D / G, S352N / G, D379V according to the numbering of SEQ ID NO: 35.

[0226] Preferably, the mannanase comprises at least one of amino acid substitution Q89V and N96D and one or more amino acid substitutions selected from A31 V, A119Y / H / T, E264Q / V, W289F / M / H, and N312F / Y according to the numbering of SEQ ID NO: 35.

[0227] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119Y / H / T, X264Q / V, X289F / M / H, X312F / Y, X348S / R / N / M / G, X349T / S / D / G, and X352N / G according to the numbering of SEQ ID NO: 35.

[0228] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions Q89V, N96D, A119Y / H / T, E264Q / V, W289F / M / H, N312F / Y, T348S / R / N / M / G, E349T / S / D / G, and S352N / G according to the numbering of SEQ ID NO: 35.

[0229] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119Y / H / T, X264Q / V, X289F / M / H, X312F / Y, X348S / R / N / M / G, X349T / S / D / G, and X352N / G according to the numbering of SEQ ID NO: 35.

[0230] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions Q89V, N96D, A119Y / H / T, E264Q / V, W289F / M / H, N312F / Y, T348S / R / N / M / G, E349T / S / D / G, and S352N / G according to the numbering of SEQ ID NO: 35.

[0231] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35.

[0232] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35.

[0233] More preferably, the mannanase variant comprises the amino acid substitutions X89V, X96D, X119H, X264Q, X289M, and X312Y according to the numbering of SEQ ID NO: 35. More preferably, the mannanase variant comprises the amino acid substitutions Q89V, N96D, A119H, E264Q, W289M, and N312Y according to the numbering of SEQ ID NO: 35.

[0234] Most preferably, the mannanase variant comprises the amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35.

[0235] Most preferably, the mannanase variant comprises the amino acid substitutions Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35.

[0236] Preferably, the mannanase variant further comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35.

[0237] Preferably, the mannanase variant further comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of X341 F, X346T, X348S / R / N / M / G, X349T / S / G / D, X352N / G, X356Y / V / T / Q / H / C, and X379V according to the numbering of SEQ ID NO: 35.

[0238] Preferably, the mannanase variant further comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of N341 F, F346T, T348S / R / N / M / G, E349T / S / G / D, S352N / G, G356Y / V / T / Q / H / C, and D379V according to the numbering of SEQ ID NO: 35.

[0239] Preferably, the mannanase variant comprises an amino acid sequence which is at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to any of the amino acid sequences shown in SEQ ID NO: 35-37 or to a sequence according to positions 31-490 of SEQ ID NO: 35, preferably to a sequence according to positions 31-490 of SEQ ID NO: 35. More preferably, the mannanase variant comprises an amino acid sequence which is at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35.

[0240] Most preferably, the mannanase variant comprises an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35.

[0241] Preferably, the mannanase of the enzyme composition is a mannanase variant of a parent mannanase, wherein the mannanase variant comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and an amino acid sequence which is at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to any of the amino acid sequences shown in SEQ ID NO: 35-37 or to a sequence according to positions 31-490 of SEQ ID NO: 35, preferably to a sequence according to positions 31-490 of SEQ ID NO: 35.

[0242] Preferably, the mannanase of the enzyme composition is a mannanase variant of a parent mannanase, wherein the mannanase variant comprises an amino acid substitution at one or more amino acid positions selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35.

[0243] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of X86N, X89V / L, X96D, X101T / V, X103Y / E / A, X107N, X108G, X109Q / A, X112N, X119Y / H / T, X122S, X124E / C / D, X126E, X127A, X129M / L / F, X231Q / K / L / P / Y, X233V, X235H / R / L / Q / N / Y, X244I / V / N, X254W, X255Y / H / R, X264Q / V, X270T, X272I, X273T, X274E / C / Q, X281 L, X286E / L / Q / A, X289F / M / H, X290A, X296H / F / Y, X301 E / C / T, X309L, X312F / Y, X314P, X317T, and X319D / E according to the numbering of SEQ ID NO: 35 an amino acid sequence which is at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to any of the amino acid sequences shown in SEQ ID NO: 35-37 or to a sequence according to positions 31-490 of SEQ ID NO: 35, preferably to a sequence according to positions 31-490 of SEQ ID NO: 35.

[0244] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of X86N, X89V / L, X96D, X101T / V, X103Y / E / A, X107N, X108G, X109Q / A, X112N, X119Y / H / T, X122S, X124E / C / D, X126E, X127A, X129M / L / F, X231Q / K / L / P / Y, X233V, X235H / R / L / Q / N / Y, X244I / V / N, X254W, X255Y / H / R, X264Q / V, X270T, X272I, X273T, X274E / C / Q, X281 L, X286E / L / Q / A, X289F / M / H, X290A, X296H / F / Y, X301 E / C / T, X309L, X312F / Y, X314P, X317T, and X319D / E according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0245] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of X86N, X89V / L, X96D, X101T / V, X103Y / E / A, X107N, X108G, X109Q / A, X112N, X119Y / H / T, X122S, X124E / C / D, X126E, X127A, X129M / L / F, X231Q / K / L / P / Y, X233V, X235H / R / L / Q / N / Y, X244I / V / N, X254W, X255Y / H / R, X264Q / V, X270T, X272I, X273T, X274E / C / Q, X281 L, X286E / L / Q / A, X289F / M / H, X290A, X296H / F / Y, X301 E / C / T, X309L, X312F / Y, X314P, X317T, and X319D / E according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0246] Preferably, the mannanase variant comprises one or more amino acid substitution selected from the group consisting of X31V, X89V, X96D, X119Y / H / T, X264Q / V, X289F / M / H, X312F / Y, X348S / R / N / M / G, X349T / S / D / G, X352N / G, and X379V according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31- 490 of SEQ ID NO: 35. More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119Y / H / T, X264Q / V, X289F / M / H, X312F / Y, X348S / R / N / M / G, X349T / S / D / G, and X352N / G according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0247] More preferably, the mannanase variant comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0248] More preferably, the mannanase variant comprises the amino acid substitutions X89V, X96D, X119H, X264Q, X289M, and X312Y according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0249] Most preferably, the mannanase variant comprises the amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0250] Most preferred is a mannanase variant comprising or consisting of the amino acid sequence according to positions 31-490 of SEQ ID NO: 35 with the amino acid substitution Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35.

[0251] In one embodiment the mannanase variant of the enzyme composition comprises

[0252] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 123, and 256 according to the numbering of SEQ ID NO: 39 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 39, or

[0253] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 10, 19, 30, 38, 59, 60, 67, 97, 103, 129, 143, 167, 168, 184, 225, 228, 235, 244, 258, 261 , and 298 according to the numbering of SEQ ID NO: 38 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 38, or

[0254] (iii) an amino acid sequence which is at least 60% identical to SEQ ID NO: 40, or

[0255] (iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 30, 81 , 93, 95, 118, 138, 139, 200, 202, 210, 260, 283, 288, 294, and 295 according to the numbering of SEQ ID NO: 40 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 40.

[0256] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 39 and comprises an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 123, and 256 according to the numbering of SEQ ID NO: 39.

[0257] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 39 and comprises one or more amino acid substitutions selected from the group consisting of X24l, X123I, and X256G, preferably the combination of X24I and X256G according to the numbering of SEQ ID NO: 39.

[0258] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 39 and comprises one or more amino acid substitutions selected from the group consisting of V24I, V123I, and S256G, preferably the combination of V24I and S256G according to the numbering of SEQ ID NO: 39.

[0259] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 38 and comprises an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 10, 19, 30, 38, 59, 60, 67, 97, 103, 129, 143, 167, 168, 184, 225, 228, 235, 244, 258, and 261 , preferably in combination with the deletion at position 298*, according to the numbering of SEQ ID NO: 38.

[0260] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 38 and comprises one or more amino acid substitutions selected from the group consisting of X10T, X19P, X30S, X38T, X59S, X60L, X67N, X97N, X103V, X129Y, X143Q, X167F, X168S, X184Q, X225P / G, X228T, X235Y, X244K, X258S, and X261 N, preferably in combination with the deletion X298*, according to the numbering of SEQ ID NO: 38.

[0261] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 38 and comprises one or more amino acid substitutions selected from the group consisting of N10T, E19P, T30S, E38T, V59S, Q60L, D67N, D97N, 1103V, M129Y, K143Q, Y167F, P168S, L184Q, C225P / G, V228T, L235Y, L244K, D258S, and R261 N, preferably in combination with the deletion Q298*, according to the numbering of SEQ ID NO: 38.

[0262] In one embodiment, the mannanase variant has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 40.

[0263] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 40 and comprises an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 30, 81 , 93, 95, 118, 138, 139, 200, 202, 210, 260, 283, 288, 294, and 295, preferably amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 260, 288, 294, and 295, according to the numbering of SEQ ID NO: 40.

[0264] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 40 and comprises one or more amino acid substitutions selected from the group consisting of X30T, X81 P, X93Q, X95D, X118K, X138P, X139R, X200T, X202R, X210G, X260F, X283H, X288I, X294P, and X295V, preferably one or more amino acid substitutions selected from the group consisting of X260F, X288I, X294P, and X295V, according to the numbering of SEQ ID NO: 40.

[0265] In one embodiment, the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 40 and comprises one or more amino acid substitutions selected from the group consisting of A30T, L81 P, Y93Q, S95D, D118K, A138P, D139R, N200T, S202R, R210G, W260F, N283H, L288I, L294P, and S295V, preferably one or more amino acid substitutions selected from the group consisting of W260F, L288I, L294P, and S295V, according to the numbering of SEQ ID NO: 40.

[0266] Mannanases with substitutions as described above are shown for instance in SEQ ID NO: 41. Thus, in one embodiment the mannanase variant comprises an amino acid sequence which is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 41.

[0267] Cellulases

[0268] In one embodiment, the enzyme composition of the present invention comprises a cellulase. The cellulases and cellulase variants described herein have cellulase activity. "Cellulases" are enzymes capable of hydrolysing cellulose. Cellulases may be selected from cellobiohydrolases (1 ,4-P-D-glucan cellobiohydrolase, EC 3.2.1.91), endo-ss-1 ,4-glucanases (EC 3.2.1.4) and ss- glucosidases (EC 3.2.1.21). Endoglucanases of EC class 3.2.1.4 may be named endoglu- canases, endo-1 ,4-ss-D-glucan 4-glucano hydrolases, endo-1 ,4-beta-glucanases, carboxymethyl cellulases, and beta-1 , 4-glucanases.

[0269] Endoglucanases may be classified by amino acid sequence similarities (Henrissat, B. Accessed at UniProt 10 / 26 / 2011) as family 5 that contains more than 20 endoglucanases of EC 3.2.1.4. Reference is also made to T.-M. Enveri, "Microbial Cellulases" in W.M. Fogarty, Microbial Enzymes and Biotechnology, Applied Science Publishers, p. 183-224 (1983); Methods in Enzymol- ogy, (1988) Vol. 160, p. 200-391 (edited by Wood, W.A. and Kellogg, S.T.); Beguin, P., "Molecular Biology of Cellulose Degradation", Annu. Rev. Microbiol. (1990), Vol. 44, pp. 219248; Begun, P. and Aubert, J-P., "The biological degradation of cellulose", FEMS Microbiology Reviews 13 (1994) p.25-58; Henrissat, B., "Cellulases and their interaction with cellulose", Cellulose (1994), Vol. 1 , pp. 169-196.

[0270] The cellulase of the enzyme composition is selected from

[0271] - a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 42, and

[0272] - a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 46, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 44, or SEQ ID NO: 47.

[0273] Preferably, the cellulase variant of the enzyme composition is a cellulase comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 42.

[0274] Preferably, the cellulase variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 42.

[0275] Preferably, the cellulase variant has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 42.

[0276] Preferably, the cellulase variant has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 42.

[0277] Most preferably the cellulase variant comprises or consists of SEQ ID NO: 42.

[0278] In one embodiment the cellulase of the enzyme composition has an amino acid sequence which is at least 60% identical to SEQ ID NO: 46, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 44, or SEQ ID NO: 47.

[0279] Preferably, the cellulase variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown SEQ ID NO: 43-47.

[0280] Preferably, the cellulase variant has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown SEQ ID NO: 43-47.

[0281] Preferably, the cellulase variant has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown in SEQ ID NO: 43-47.

[0282] In one embodiment, the cellulase according to the present invention preferably has at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 46.

[0283] In one embodiment, the cellulase variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 43.

[0284] In one embodiment, the cellulase variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 45.

[0285] In one embodiment, the cellulase variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 44.

[0286] In one embodiment, the cellulase variant has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity to any of the amino acid sequences shown in SEQ ID NO: 47. Preferred herein is a composition comprising two or more enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is selected from

[0287] I. a protease variant of a parent protease, wherein the protease variant comprises

[0288] (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0289] (ii) an amino acid sequence which is at least 80%, but less than 100% identical to any of SEQ ID NO: 16, or

[0290] II. a protease variant of a parent protease, wherein the protease variant comprises

[0291] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 3, 4, 9, 19, 22, 43, 62, 63, 76, 87, 99, 101 , 103, 104, 116, 118, 128, 129, 130, 156, 160, 167, 170, 182, 185, 188, 194, 205, 213, 217, 218, 232, 245, 256, 259, 262, and 271 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 22, or

[0292] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 53, 76, 78, 101 , 128, and 217 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 17, or

[0293] (iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 89, 130, 133, 144, 159, 183, 189. 217, 224, 238, 243, 252, 259, 270 and 271 according to the numbering of SEQ ID NO: 19 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 19, or

[0294] (iv) an amino acid sequence which has at least 60% sequence identity with SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31 , b. the mannanase is selected from

[0295] I. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and

[0296] (ii) an amino acid sequence which is at least 80%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, or

[0297] II. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0298] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 123, and 256 according to the numbering of SEQ ID NO: 39 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 39, or

[0299] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 10, 19, 30, 38, 59, 60, 67, 97, 103, 129, 143, 167, 168, 184, 225, 228, 235, 244, 258, 261 , and 298 according to the numbering of SEQ ID NO: 38 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 38, or

[0300] (iii) an amino acid sequence which is at least 60% identical to SEQ ID NO: 40, or

[0301] (iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 30, 81 , 93, 95, 118, 138, 139, 200, 202, 210, 260, 283, 288, 294, and 295 according to the numbering of SEQ ID NO: 40 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 40, c. the cellulase is selected from

[0302] I. a cellulase variant comprising an amino acid sequence which is at least 80% identical to SEQ ID NO: 42, or

[0303] II. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 46, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 44, or SEQ ID NO: 47, and wherein at least one enzyme is selected from the group consisting of aa. a protease variant of a parent protease, wherein the protease variant comprises (i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and

[0304] (ii) an amino acid sequence which is at least 80%, but less than 100% identical to SEQ ID NO: 16, bb. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises

[0305] (i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and

[0306] (ii) an amino acid sequence which is at least 80%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and cc. a cellulase variant comprising amino acid sequence which is at least 80% identical to SEQ ID NO: 42.

[0307] Preferably, the protease variant has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises compared to SEQ ID NO: 16 the amino acid substitution X101 D or X101 E, preferably X101 E, preferably R101 E, according to the numbering of SEQ ID NO: 17. In a specific embodiment, the protease variant comprises the amino acid substitution X101 E and the amino acid substitutions X3T, X4I, and X205I or the amino acid substitutions X156D and X262E according to the numbering of SEQ ID NO: 17, and an amino acid sequence which is at least 90%, but less than 100% identical to SEQ ID NO: 16.

[0308] Alternatively, the protease variant comprises an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 22 and one or more amino acid substitutions selected from the group consisting of X3T, X4I, X9D / E / R, X19L, X22R / A, X43R, X62D, X63D / E, X76D, X87N, X99A / D, X101 M / R / E, X103A, X104I, X116L, X118V, X128L, X129Q, X130A, X156D / E, X160D / S, X167A, X170S, X182E / D, X185E / D, X188D, X194P, X205I, X213A, X217E / D / Q, X218D, X232V, X245R, X256D / E, X259D / E, X262D / E, and X271 F according to the numbering of SEQ ID NO: 17, preferably the protease variant further comprises an insertion of D and E directly adjacent C-terminally of the position 99 according to the numbering of SEQ ID NO: 17, preferably, the protease variant comprises an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to any of SEQ ID NO: 24.

[0309] Preferably, the mannanase variant comprises the amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35 and an amino acid sequence which is at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to the amino acid sequence according to positions 31-490 of SEQ ID NO: 35.

[0310] Alternatively, the mannanase variant comprises an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 40 and comprises one or more amino acid substitutions selected from the group consisting of X30T, X81 P, X93Q, X95D, X118K, X138P, X139R, X200T, X202R, X210G, X260F, X283H, X288I, X294P, and X295V, preferably one or more amino acid substitutions selected from the group consisting of X260F, X288I, X294P, and X295V, according to the numbering of SEQ ID NO: 40, preferably the mannanase variant comprises an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 41.

[0311] Preferably, the cellulase comprises an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42.

[0312] Prefered herein is a composition comprising two or three enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is a protease variant comprising

[0313] (i) the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and

[0314] (ii) an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 16, or the protease is a protease variant comprising the amino acid substitution X101 E and the amino acid substitutions X3T, X4I, and X205I or the amino acid substitutions X156D and X262E according to the numbering of SEQ ID NO: 17, and an amino acid sequence which is at least 90%, but less than 100% identical to SEQ ID NO: 16, or the protease is a protease variant comprising an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 22 and one or more amino acid substitutions selected from the group consisting of X3T, X4I, X9D / E / R, X19L, X22R / A, X43R, X62D, X63D / E, X76D, X87N, X99A / D, X101 M / R / E, X103A, X104I , X116L, X118V, X128L, X129Q, X130A, X156D / E, X160D / S, X167A, X170S, X182E / D, X185E / D, X188D, X194P, X205I, X213A, X217E / D / Q, X218D, X232V, X245R, X256D / E, X259D / E, X262D / E, and X271 F according to the numbering of SEQ ID NO: 17, preferably the protease variant further comprises an insertion of D and E directly adjacent C-terminally of the position 99 according to the numbering of SEQ ID NO: 17, preferably, the protease variant comprises an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least

[0315] 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least

[0316] 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least

[0317] 99%, at least 99.5%, or 100% identical to any of SEQ ID NO: 24, b. the mannanase is a mannanase variant comprising (i) at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35, and

[0318] (ii) an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to a sequence according to positions 31 -490 of SEQ ID NO: 35, or the mannanase is a mannanase variant comprising an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, but less than 100% identical to SEQ ID NO: 40 and comprises one or more amino acid substitutions selected from the group consisting of X30T, X81 P, X93Q, X95D, X118K, X138P, X139R, X200T, X202R, X210G, X260F, X283H, X288I, X294P, and X295V, preferably one or more amino acid substitutions selected from the group consisting of X260F, X288I, X294P, and X295V, according to the numbering of SEQ ID NO: 40, preferably the mannanase variant comprises an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 41 , c. the cellulase is a cellulase variant comprising an amino acid sequence which is at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least

[0319] 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least

[0320] 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least

[0321] 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42.

[0322] More preferred herein is a composition comprising two or three enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is a protease variant comprising

[0323] (i) the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and

[0324] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to SEQ ID NO: 16, b. the mannanase is a mannanase variant comprising

[0325] (i) at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35, and

[0326] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and c. the cellulase is a cellulase variant comprising an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42.

[0327] Thus, more preferred herein is a composition comprising a protease and a mannanase, wherein a. the protease is a protease variant comprising

[0328] (i) the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to SEQ ID NO: 16, and b. the mannanase is a mannanase variant comprising

[0329] (i) at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35, and

[0330] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35.

[0331] Thus, more preferred herein is a composition comprising a protease and a cellulase, wherein a. the protease is a protease variant comprising

[0332] (i) the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and

[0333] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to SEQ ID NO: 16, and b. the cellulase is a cellulase variant comprising an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42.

[0334] Thus, more preferred herein is a composition comprising a mannanase and a cellulase, wherein a. the mannanase is a mannanase variant comprising

[0335] (i) at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35, and

[0336] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and b. the cellulase is a cellulase variant comprising an amino acid sequence which is at least

[0337] 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least

[0338] 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least

[0339] 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least

[0340] 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least

[0341] 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42.

[0342] More preferred herein is a composition comprising two or three enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E according to the numbering of SEQ ID NO: 17, i.e. , only one amino acid exchange compared to SEQ ID NO: 16, b. the mannanase is a mannanase variant comprising or consisting of the amino acid sequence according to positions 31-490 of SEQ ID NO: 35 with the amino acid substitution Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35, c. the cellulase is a cellulase variant comprising or consisting of an amino acid sequence which is 100% identical to SEQ ID NO: 42.

[0343] Thus, more preferred herein is a composition comprising a protease and a mannanase, wherein a. the protease is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E according to the numbering of SEQ ID NO: 17, i.e., only one amino acid exchange compared to SEQ ID NO: 16, and b. the mannanase is a mannanase variant comprising or consisting of the amino acid sequence according to positions 31-490 of SEQ ID NO: 35 with the amino acid substitution Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35.

[0344] Thus, more preferred herein is a composition comprising a protease and a cellulase, wherein a. the protease is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E according to the numbering of SEQ ID NO: 17, i.e., only one amino acid exchange compared to SEQ ID NO: 16, and b. the cellulase is a cellulase variant comprising or consisting of an amino acid sequence which is 100% identical to SEQ ID NO: 42.

[0345] Thus, more preferred herein is a composition comprising a mannanase and a cellulase, wherein a. the mannanase is a mannanase variant comprising or consisting of the amino acid sequence according to positions 31-490 of SEQ ID NO: 35 with the amino acid substitution Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35, and b. the cellulase is a cellulase variant comprising or consisting of an amino acid sequence which is 100% identical to SEQ ID NO: 42.

[0346] Preferably, the composition comprises a protease and a mannanase as described herein, a protease and a cellulase as described herein, or a protease, a mannanase, and a cellulase as described herein.

[0347] Even more preferably, the composition comprises a protease, a mannanase, and a cellulase, wherein a. the protease is a protease variant comprising

[0348] (i) the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least

[0349] 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least

[0350] 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least

[0351] 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least

[0352] 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to SEQ ID NO: 16, b. the mannanase is a mannanase variant comprising

[0353] (i) at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35, and

[0354] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least

[0355] 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least

[0356] 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least

[0357] 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least

[0358] 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least

[0359] 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and c. the cellulase is a cellulase variant comprising an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least

[0360] 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least

[0361] 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least

[0362] 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least

[0363] 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42.

[0364] Most preferably, the composition comprises a protease, a mannanase, and a cellulase, wherein a. the protease is a protease variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 16 with the amino acid substitution R101 E according to the numbering of SEQ ID NO: 17, i.e. , only one amino acid exchange compared to SEQ ID NO: 16, b. the mannanase is a mannanase variant comprising or consisting of the amino acid sequence according to positions 31-490 of SEQ ID NO: 35 with the amino acid substitution Q89V, N96D, A119H, E264Q, W289M, N312Y, T348N, E349G, and S352G according to the numbering of SEQ ID NO: 35, and c. the cellulase is a cellulase variant comprising or consisting of an amino acid sequence which is 100% identical to SEQ ID NO: 42.

[0365] Further enzymes

[0366] In another embodiment, the composition comprising the enzyme composition as described herein further comprises one or more further enzyme different from the enzymes of the enzyme composition described herein. Preferably, the further enzyme is selected from the group consisting of proteases, amylases, lipases, cellulases, mannanases, hemicellulases, phospholipases, esterases, pectinases, lactases, peroxidases, xylanases, cutinases, pectate lyases, keratinases, reductases, oxidases, phenoloxidases, lipoxygenases, ligninases, pullulanases, tannases, pen- tosanases, malanases, beta-glucanases, arabinosidases, hyaluronidases, chondroitinases, laccases, nucleases, DNase, phosphodiesterases, phytases, carbohydrases, galactanases, xan- thanases, xyloglucanases, oxidoreductase, perhydrolases, aminopeptidase, asparaginase, carbohydrase, carboxypeptidase, catalase, chitinase, cyclodextrin glycosyltransferase, alpha-ga- lactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, ribonuclease, transglutaminase, and dispersins, and combinations of at least two of the foregoing types. More preferably, the further enzyme is selected from the group consisting of amylases, lipases, hemicellulases, xylanases, DNases, dispersins, pectinases, oxidoreductases, cutinases, phosphodiesterases, licheninases, xanthan-lyases, and hexosaminidases, and combinations of at least two of the foregoing types. Most preferably, the additional enzyme is an amylase and / or a lipase, preferably an amylase.

[0367] Amylases

[0368] The enzyme composition of the present invention may comprises an amylase. In another embodiment, the enzyme composition does not comprise an amylase.

[0369] Amylases and amylase variants described herein have amylase activity (also called herein “amylolytic activity”). “Amylolytic activity” or “amylase activity” describes the capability for the hydrolysis of glucosidic linkages in polysaccharides. Amylase activity may be determined by assays for measurement of amylase activity which are known to those skilled in the art. Examples for assays measuring amylase activity are the Phadebas assay or the EPS assay (“Infinity reagent”). In the Phadebas assay amylase activity is determined by employing Phadebas tablets as substrate (Phadebas Amylase Test, supplied by Magle Life Science). Starch is hydrolyzed by the amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at 620 nm, is a function of the amylase activity. The measured absorbance is directly proportional to the specific activity (activity / mg of pure amylase protein) of the amylase in question under the given set of conditions.

[0370] Alternatively, amylase activity can also be determined by a method employing the Ethyliden-4- nitrophenyl-alpha-D-maltoheptaosid (EPS). D-maltoheptaoside is a blocked oligosaccharide which can be cleaved by an endo-amylase. Following the cleavage, the alpha-glucosidase included in the kit digests the substrate whichliberates a free PNP molecule which has a yellow color and thus can be measured by visible spectophotometry at 405 nm. Kits containing EPS substrate and alpha-glucosidase are manufactured for example by Roche Costum Biotech (cat. No. 10880078103). The slope of the time dependent absorption-curve is directly proportional to the specific activity (activity per mg enzyme) of the amylase in question under the given set of conditions.

[0371] The amylase may be selected from

[0372] - an amylase variant of a parent amylase, wherein said amylase variant comprises

[0373] (i) an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2, and

[0374] (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 4, 116, 176, 181 , 186, 195, 206, 225, 251 , 320, 405, and 482 according to the numbering of SEQ ID NO: 2,

[0375] (iii) at least 60%, preferably at least 91% identity, but less than 100% sequence identity with any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0376] - an amylase variant of a parent amylase, wherein said amylase variant comprises

[0377] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 183, 243, 266 and 475 according to the numbering of SEQ ID NO: 9 and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 9, or

[0378] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 38, 126, 129, 153, 180, 187, 199, 203, 241 , 362, 377, 458, 459, 460, 476 and 477 according to the numbering of SEQ ID NO: 7 and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 7, or (iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 7, 51 , 52, 54, 109, 140, 195, 206, 243, 260, 280, 284, 304, 391 , 476 and 477 according to the numbering of SEQ ID NO: 3 and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 3, or

[0379] (iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 458 and 471 according to the numbering of SEQ ID NO: 13 and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 13, or

[0380] (v) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 149, 167, 172, 174, 182, 195, 202, 206, 246, 257, 295, 299, 320, 339, 345, 391 , 458, 471 , 473 and 476 according to the numbering of SEQ ID NO: 15 and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 15, or

[0381] (vi) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 405, 421 ,422,428, 458 and 471 according to the numbering of SEQ ID NO: 4 and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 4, or

[0382] (vii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 120, 134, 140, 167, 169, 172, 173, 174, 182, 183, 184, 195, 202, 206, 246, 255, 257, 260, 265, 295, 299, 304, 320, 339, 345, 391 , 395, 410, 422, 429, 444, 451 , 458, 473, 474 and 476 according to the numbering of SEQ ID NO: 5; and an amino acid sequence which is at least 60%, but less than 100% sequence identity to SEQ ID NO: 5.

[0383] The amylase variant is a non-naturally occurring amylase. Preferably, the amylase variant is a purified, isolated, synthetic, and / or recombinant amylase variant. Preferably, the amylase variant is a purified and recombinant amylase variant.

[0384] Preferably, the parent amylase for the amylase variant is an amylase having at least 60% sequence identity to any of SEQ ID NO: 1-15, preferably the parent amylase for the amylase variant is an amylase according to any of SEQ ID NO: 1-15. Most preferably the parent amylase for the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1.

[0385] Preferably, the amylase variant additionally comprises a deletion at one or more, preferably at two or more, amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184. Preferably, the amylase variant of the present invention having one or more amino acid substitutions as described herein comprises a deletion of one or more amino acids corresponding to positions 183 and 184, preferably a deletion of both amino acids corresponding to positions 183 and 184 (according to the numbering of SEQ ID NO: 2). Preferably, the amylase variant of the present invention having one or more amino acid substitutions as described herein comprises a deletion of one or more, preferably of two or more, most preferably of two, amino acids corresponding to positions selected from the group consisting of R181 , G182, D183, and G184, preferably D183* and G184*, wherein the numbering is according to the amino acid sequence set forth in SEQ ID NO: 2.

[0386] Preferably, the amylase variant comprises a deletion at two amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184*, wherein the numbering is according to SEQ ID NO: 2.

[0387] The present invention is directed to an amylase variant of a parent amylase having amylase activity, wherein said variant comprises compared to the parent amylase amino acid alteration, preferably insertion, deletion, substitution, or combination thereof, most preferably substitution, at two or more positions corresponding to positions selected from the group consisting of 4, 25, 116, 176, 181 , 186, 195, 206, 225, 251 , 320, 405, and 482 according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2.

[0388] In an alternative way, one can describe the amino acid positions 4, 25, 116, 176, 181 , 186, 195, 206, 225, 251 , 320, 405, and 482 (according to the numbering of SEQ ID NO: 2) with reference to the numbering of SEQ ID NO: 1 , i.e., according to the numbering of SEQ ID NO: 1. In this alternative way of describing the amino acid positions of the present invention, amino acid positions 4, 25, 176, 186, 251 , 405, and 482 according to the numbering of SEQ ID NO: 2 correspond to amino acid positions 4, 25, 116, 176, 181 , 184, 193, 204, 223, 249, 318, 403, and 480 according to the numbering of SEQ ID NO: 1 . Preferably, the parent amylase for the amylase variant is an amylase having at least 60% sequence identity with SEQ IDNO: 1 or SEQ ID NO: 2, or any of SEQ ID NO: 3-15, preferably the parent amylase for the amylase variant is an amylase according to SEQ IDNO: 1 or SEQ ID NO: 2, or any of SEQ ID NO: 3-15. Most preferably the parent amylase for the amylase variant is an amylase according to SEQ ID NO: 1.

[0389] Preferably, the present invention is directed to an amylase variant comprising one or more amino acid substitutions selected from the group consisting of X4Q, X25H, X116K, X176K, X186E, X195F, X206Y, X225A, X251 E, X320K, X405M, and X482W according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2.

[0390] Preferably, the present invention is directed to an amylase variant comprising compared to a parent sequence one or more amino acid substitutions selected from the group consisting of X4Q, X25H, X116K, X176K, X186E, X195F, X206Y, X225A, X251 E, X320K, X405M, and X482W according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2 and wherein said variant has amylase activity, preferably wherein the parent amylase for the amylase variant is an amylase according to SEQ ID NO: 1 or any amylase having at least 60% sequence identity with SEQ IDNO: 1 , most preferably the parent amylase for the amylase variant is an amylase according to SEQ ID NO: 1.

[0391] Preferably, in this embodiment, the amino acid residue in the parent amylase at the above cited positions (i.e. , X) corresponds to the amino acid residue shown in SEQ ID NO: 1 at the respective position according to the numbering of SEQ ID NO: 2.

[0392] Thus, preferably, the present invention is directed to an amylase variant comprising an amino acid substitution at one or more positions corresponding to positions selected from the group consisting of G4, N25, W116, R176, R181 , G186, N195, I206, T225, T251 , R320, L405, and Y482 according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2.

[0393] In a preferred embodiment, the present invention is directed to an amylase variant comprising an amino acid substitution at one or more positions corresponding to positions selected from the group consisting of G4Q, N25H, W116K, R176K, R181T, G186E, N195F, I206Y, T225A, T251 E, R320K, L405M, and Y482W according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2.

[0394] The present invention is preferably directed to an amylase variant comprising an amino acid substitution at position 25 and at one or more positions corresponding to positions selected from the group consisting of 4, 116, 176, 181 , 186, 195, 206, 225, 251 , 320, 405, and 482 according to the numbering of SEQ ID NO: 2.

[0395] Preferably, the present invention is directed to an amylase variant comprising the amino acid substitution X25H and one or more amino acid substitutions selected from the group consisting of X4Q, X116K, X176K, X186E, X195F, X206Y, X225A, X251 E, X320K, X405M, and X482W according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2.

[0396] Thus, preferably, the present invention is directed to an amylase variant comprising an amino acid substitution at the amino acid position N25 and at one or more positions corresponding to positions selected from the group consisting of G4, W116, R176, R181 , G186, N195, I206, T225, T251 , R320, L405, and Y482 according to the numbering of SEQ ID NO: 2.

[0397] In a preferred embodiment, the present invention is directed to an amylase variant comprising the amino acid substitution N25H and amino acid substitutions at one or more positions corresponding to positions selected from the group consisting of G4Q, W116K, R176K, R181T, G186E, N195F, I206Y, T225A, T251 E, R320K, L405M, and Y482W according to the numbering of SEQ ID NO: 2.

[0398] Preferably, the amylase variant comprises compared to the parent amylase an amino acid substitution at one or more of the amino acid positions (according to the numbering of the amino acid sequence set forth in SEQ ID NO: 2) described below. Preferably, the parent amylase for the amylase variant is an amylase according to any of SEQ ID NO: 1-15, most preferably the parent amylase for the amylase variant is an amylase according to SEQ ID NO: 1 . Preferably, the amino acid residue of the parent amylase at the cited positions (i.e. , X) corresponds to the amino acid residue shown in SEQ ID NO: 2 at the respective position (according to the numbering of SEQ ID NO: 2).

[0399] The amylase variant preferably comprises an amino acid substitution at position 25 (according to the numbering of SEQ ID NO: 2), preferably the substitution X25H. Alternatively, the acid substitution at position 25 is X25Y or X25D.

[0400] Preferably, the amylase variant comprises an amino acid substitution at position 4 (according to the numbering of SEQ ID NO: 2), preferably the substitution X4Q. Preferably, the amylase variant comprises an amino acid substitution at position 116 (according to the numbering of SEQ ID NO: 2), preferably the substitution X116K.

[0401] Preferably, the amylase variant comprises an amino acid substitution at position 176 (according to the numbering of SEQ ID NO: 2), preferably the substitution X176K.

[0402] Preferably, the amylase variant comprises an amino acid substitution at position 181 (according to the numbering of SEQ ID NO: 2), preferably the substitution X181T.

[0403] Preferably, the amylase variant comprises an amino acid substitution at position 186 (according to the numbering of SEQ ID NO: 2), preferably the substitution X186E.

[0404] Preferably, the amylase variant comprises an amino acid substitution at position 195 (according to the numbering of SEQ ID NO: 2), preferably the substitution X195F.

[0405] Preferably, the amylase variant comprises an amino acid substitution at position 206 (according to the numbering of SEQ ID NO: 2), preferably the substitution X206Y.

[0406] Preferably, the amylase variant comprises an amino acid substitution at position 225 (according to the numbering of SEQ ID NO: 2), preferably the substitution X225A.

[0407] Preferably, the amylase variant comprises an amino acid substitution at position 251 (according to the numbering of SEQ ID NO: 2), preferably the substitution X251 E.

[0408] Preferably, the amylase variant comprises an amino acid substitution at position 320 (according to the numbering of SEQ ID NO: 2), preferably the substitution X320K.

[0409] Preferably, the amylase variant comprises an amino acid substitution at position 405 (according to the numbering of SEQ ID NO: 2), preferably the substitution X405M.

[0410] Preferably, the amylase variant comprises an amino acid substitution at position 482 (according to the numbering of SEQ ID NO: 2), preferably the substitution X482W.

[0411] In one embodiment, the amylase variant of a parent amylase comprises

[0412] (i) an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2,

[0413] (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 116, 176, 181 , 186, 195, 206, 225, 320, and 482 according to the numbering of SEQ ID NO: 2, and

[0414] (iii) at least 60%, preferably at least 91 % identity, but less than 100% sequence identity with SEQ ID NO: 1-15, preferably of SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 . Preferably, the amylase variant comprises an amino acid substitution at position 25 and an amino acid substitution at one or more positions selected from the group consisting of 116, 181 , 225, and 320 according to the numbering of SEQ ID NO: 2.

[0415] Preferably, the amylase variant comprises an amino acid substitution at position 25 and an amino acid substitution at one or more positions selected from the group consisting of 176 and 186 according to the numbering of SEQ ID NO: 2.

[0416] Preferably, the amylase variant comprises an amino acid substitution at position 25 and an amino acid substitution at one or more positions selected from the group consisting of 195 or 206 according to the numbering of SEQ ID NO: 2.

[0417] Preferably, the amylase variant comprises an amino acid substitution at position 25 and an amino acid substitution at position 482 according to the numbering of SEQ ID NO: 2.

[0418] Preferably, said amino acid substitution at position 25 is X25H.

[0419] Preferably, said amino acid substitution at position 116 is X116K, preferably said amino acid substitution at position 176 is X176K, preferably said amino acid substitution at position 181 is X181T, preferably said amino acid substitution at position 186 is X186E, preferably said amino acid substitution at position 195 is X195F, preferably said amino acid substitution at position 206 is X206Y, preferably said amino acid substitution at position 225 is X225A, preferably said amino acid substitution at position 320 is X320K, and preferably said amino acid substitution at position 482 is X482W.

[0420] Preferably, the amylase variant comprises an amino acid substitution at position 25, preferably X25H, and (according to the numbering of SEQ ID NO: 2) a) a substitution at one or more positions selected from 176 and 186; preferably one or more substitutions selected from X176K and X186E, or b) a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K, or c) a substitution at one or more positions selected from 176 and 186, preferably one or more substitutions selected from X176K and X186E, and a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K.

[0421] Preferably, the amylase variant comprises an amino acid substitution at position 25, preferably X25H, and (according to the numbering of SEQ ID NO: 2) a) a substitution at one or more positions selected from 176 and 186; preferably one or more substitutions selected from X176K and X186E, or b) a substitution at one or more positions selected from 176 and 186, preferably one or more substitutions selected from X176K and X186E, and a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K.

[0422] Preferably, the amylase variant comprises an amino acid substitution at position 25, preferably X25H, and (according to the numbering of SEQ ID NO: 2) a) a substitution at amino acid position 195, preferably X195F, or a substitution at amino acid position 206, preferably X206Y, and a substitution at one or more positions selected from

[0423] 176 and 186; preferably one or more substitutions selected from X176K and X186E, or b) a substitution at amino acid position 195, preferably X195F, or a substitution at amino acid position 206, preferably X206Y, and a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K, or c) a substitution at amino acid position 195, preferably X195F, or a substitution at amino acid position 206, preferably X206Y, and a substitution at one or more positions selected from

[0424] 176 and 186, preferably one or more substitutions selected from X176K and X186E, and a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K.

[0425] Preferably, the amylase variant comprises an amino acid substitution at position 25, preferably X25H, and (according to the numbering of SEQ ID NO: 2) a) a substitution at amino acid position 195, preferably X195F, or a substitution at amino acid position 206, preferably X206Y, and a substitution at one or more positions selected from 176 and 186; preferably one or more substitutions selected from X176K and X186E, or b) a substitution at amino acid position 195, preferably X195F, or a substitution at amino acid position 206, preferably X206Y, and a substitution at one or more positions selected from 176 and 186, preferably one or more substitutions selected from X176K and X186E, and a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K.

[0426] Preferably, the amylase variant comprises an amino acid substitution at position 25, preferably X25H, and (according to the numbering of SEQ ID NO: 2) a) a substitution at amino acid position 195, preferably X195F, and a substitution at one or more positions selected from 176 and 186; preferably one or more substitutions selected from X176K and X186E, or b) a substitution at amino acid position 195, preferably X195F, and a substitution at one or more positions selected from 176 and 186, preferably one or more substitutions selected from X176K and X186E, and a substitution at one or more positions selected from 116, 181 , 225, and 320, preferably one or more substitutions selected from X116K, X225A, and X320K.

[0427] Preferably, the amylase variant comprises

[0428] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2, and

[0429] (ii) one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2.

[0430] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0431] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0432] (ii) the amino acid substitution eitherX195F or X206Y according to the numbering of SEQ ID NO: 2,

[0433] (iii) one or more, two or more, three or more, four or more, five or more, six or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2. Preferably, the amylase variant comprises one of the following combinations of amino acid substitutions (according to the numbering of SEQ ID NO: 2):

[0434] Most preferred, the amylase variant comprises one of the following combinations of amino acid substitutions X25H+X116K+X176K+X181T+X186E+X195F+X225A+X320K+X482W (according to the numbering of SEQ ID NO: 2).

[0435] Preferably, the amylase variant comprises one of the following combinations of amino acid substitutions (according to the numbering of SEQ ID NO: 2):

[0436] Most preferred, the amylase variant comprises the following combination of amino acid substitutions X25H+X116K+X176K+X181T+X186E+X206Y+X225A+X320K+X482W (according to the numbering of SEQ ID NO: 2). In one embodiment, the amylase variant of a parent amylase comprises

[0437] (i) an amino acid substitution at position 4 according to the numbering of SEQ ID NO: 2, (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 25, 176, 186, 251 , 405, and 482 according to the numbering of SEQ ID NO: 2, and

[0438] (iii) at least 60%, preferably at least 91 % identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably of SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 .

[0439] Preferably, the amylase variant comprises an amino acid substitution at position 4 and an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2.

[0440] Preferably, the amylase variant comprises an amino acid substitution at position 4 and an amino acid substitution at one or more positions selected from the group consisting of 176 and 186 according to the numbering of SEQ ID NO: 2.

[0441] Preferably, the amylase variant comprises an amino acid substitution at position 4 and an amino acid substitution at one or more positions selected from the group consisting of 251 and 405 according to the numbering of SEQ ID NO: 2.

[0442] Preferably, the amylase variant comprises an amino acid substitution at position 4 and an amino acid substitution at position 482 according to the numbering of SEQ ID NO: 2.

[0443] In one embodiment, the amylase variant of a parent amylase comprises

[0444] (i) an amino acid substitution at position 25 and 4 according to the numbering of SEQ ID NO: 2,

[0445] (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 176, 186, 251 , 405, and 482 according to the numbering of SEQ ID NO: 2, and

[0446] (iii) at least 60%, preferably at least 91 % identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably of SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 .

[0447] Preferably, said amino acid substitution at position 4 is X4Q. Preferably, said amino acid substitution at position 25 is X25H. Preferably, said amino acid substitution at position 176 is X176K, preferably said amino acid substitution at position 186 is X186E, preferably said amino acid substitution at position 251 is X251 E, preferably said amino acid substitution at position 405 is X405M, and preferably said amino acid substitution at position 482 is X482W.

[0448] Preferably, the amylase variant comprises (according to the numbering of SEQ ID NO: 2) a) a substitution at one or more positions selected from 25, 176, and 186; preferably one or more substitutions selected from X25H, X176K, and X186E, or b) a substitution at one or more positions selected from 251 , 405, and 482, preferably one or more substitutions selected from X251 E, X405M, and X482W, or c) a substitution at one or more positions selected from 25, 176, and 186, preferably one or more substitutions selected from X25H, X176K, and X186E, and a substitution at one or more positions selected from 251 , 405, and 482, preferably one or more substitutions selected from X251 E, X405M, and X482W.

[0449] Preferably, the amylase variant comprises

[0450] (i) the amino acid substitution X4G according to the numbering of SEQ ID NO: 2,

[0451] (ii) one or more, two or more, three or more, four or more, five or more, or all of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2.

[0452] Preferably, the amylase variant an amino acid substitution at position 4, preferably X4Q, according to the numbering of SEQ ID NO: 2, and a) a substitution at one or more positions selected from 25, 176, and 186; preferably one or more substitutions selected from X25H, X176K, and X186E, or b) a substitution at one or more positions selected from 251 , 405, and 482, preferably one or more substitutions selected from X251 E, X405M, and X482W, or c) a substitution at one or more positions selected from 25, 176, and 186, preferably one or more substitutions selected from X25H, X176K, and X186E, and a substitution at one or more positions selected from 251 , 405, and 482, preferably one or more substitutions selected from X251 E, X405M, and X482W.

[0453] Preferably, the amylase variant comprises (i) the amino acid substitution X4G according to the numbering of SEQ ID NO: 2,

[0454] (ii) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2, and

[0455] (iii) the amino acid substitution X176K and X186E according to the numbering of SEQ ID NO: 2.

[0456] Preferably, the amylase variant comprises

[0457] (i) the amino acid substitution X4G according to the numbering of SEQ ID NO: 2,

[0458] (ii) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0459] (iii) the amino acid substitution X176K and X186E according to the numbering of SEQ ID NO:

[0460] 2, and

[0461] (iv) one or more, two or more, or all of the amino acid substitutions selected from the group consisting of X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2.

[0462] Preferably, the amylase variant comprises one of the following combinations of amino acid substitutions (according to the numbering of SEQ ID NO: 2):

[0463] Most preferred, the amylase variant comprises the following combination of amino acid substitutions: X4Q+X25H+X176K+X186E+X251 E+X405M+X482W (according to the numbering of SEQ ID NO: 2).

[0464] The amylase variant according to the present invention having one or more amino acid substitutions as described herein preferably has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity to the amino acid sequence of the parent amylase.

[0465] Preferably, the amylase variant according to the present invention having one or more of the amino acid substitutions described herein preferably has at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or 2, preferably SEQ ID NO: 1.

[0466] Preferably, the amylase variant according to the present invention having one or more of the amino acid substitutions described herein preferably has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1.

[0467] Preferably, the amylase variant according to the present invention having one or more of the amino acid substitutions described herein preferably has at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1 .

[0468] In another embodiment, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , with one or more of the herein cited amino acid alterations.

[0469] In another embodiment, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , with the amino acid substitution X25H and, preferably the amino acid substitution either X195F or X206Y according to the numbering of SEQ ID NO: 2, and with 1 to 7, preferably 2 to 7 or 3 to 7, such as 1 , 2, 3, 4, 5, 6, or 7 of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2.

[0470] In another embodiment, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , with the amino acid substitution X4Q according to the numbering of SEQ ID NO: 2 and with 1 to 6, preferably 2 to 6 or 3 to 6, such as 1 , 2, 3, 4, 5, or 6 of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2.

[0471] Preferably, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , with one or more of the above cited amino acid alterations and further comprises 1 to 50, preferably 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, or 1 to 5, 2 to 30, 2 to 25, 2 to 20, 2 to 152 to 10, 2 to 8, or 2 to 5, preferably 3 to 30, 3 to 25, 3 to 20, 3 to 15 3 to 10, 3 to 8, or 3 to 5, preferably, 4 to 30, 4 to 25, 4 to 20, 4 to 15, 4 to 10, or 4 to 8 conservative amino acid exchanges, preferably including a deletion at one or more, preferably at two or more, amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 according to the numbering of SEQ ID NO: 2, as described herein.

[0472] Preferably, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , with the amino acid substitution X25H and, preferably the amino acid substitution either X195F or X206Y according to the numbering of SEQ ID NO: 2, and with 1 to 7, preferably 2 to 7 or 3 to 7, such as 1 , 2, 3, 4, 5, 6, or 7 of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2, and further comprises 1 to 50, preferably 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, or 1 to 5, 2 to 30, 2 to 25, 2 to 20, 2 to 15 2 to 10, 2 to 8, or 2 to 5, preferably 3 to 30, 3 to 25, 3 to 20, 3 to 15 3 to 10, 3 to 8, or 3 to 5, preferably, 4 to 30, 4 to 25, 4 to 20, 4 to 15, 4 to 10, or 4 to 8 conservative amino acid exchanges, preferably including a deletion at one or more, preferably at two or more, amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 according to the numbering of SEQ ID NO: 2, as described herein.

[0473] Preferably, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1 with the amino acid substitution X25H and, preferably the amino acid substitution either X195F or X206Y according to the numbering of SEQ ID NO: 2, and with 1 to 7, preferably 2 to 7 or 3 to 7, such as 1 , 2, 3, 4, 5, 6, or 7 of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2, and further comprises 1 to 10, preferably 1 to 5 conservative amino acid exchanges.

[0474] Preferably, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , with the amino acid substitution X4Q according to the numbering of SEQ ID NO: 2 and with 1 to 6, preferably 2 to 6 or 3 to 6, such as 1 , 2, 3, 4, 5, or 6 of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2, and further comprises 1 to 50, preferably 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, or 1 to 5, 2 to 30, 2 to 25, 2 to 20, 2 to 15 2 to 10, 2 to 8, or 2 to 5, preferably 3 to 30, 3 to 25, 3 to 20, 3 to 15 3 to 10, 3 to 8, or 3 to 5, preferably, 4 to 30, 4 to 25, 4 to 20, 4 to 15, 4 to 10, or 4 to 8 conservative amino acid exchanges preferably including a deletion at one or more, preferably at two or more, amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 according to the numbering of SEQ ID NO: 2, as described herein.

[0475] Preferably, the amylase variant according to the present invention having amylase activity comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1 with the amino acid substitution X4Q according to the numbering of SEQ ID NO: 2 and with 1 to 6, preferably 2 to 6 or 3 to 6, such as 1 , 2, 3, 4, 5, or 6 of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2, and further comprises 1 to 10, preferably 1 to 5 conservative amino acid exchanges. Conservative amino acid substitutions may occur over the full length of the sequence of the amylase variant. In one embodiment, such mutations are not pertaining the functional domains of the amylase variant. In one embodiment, conservative mutations are not pertaining the catalytic centers of the amylase variant.

[0476] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0477] (i) an amino acid substitution at position 4 according to the numbering of SEQ ID NO: 2,

[0478] (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 25, 176, 186, 251 , 405, and 482 according to the numbering of SEQ ID NO: 2, and

[0479] (iii) at least 60%, preferably at least 91% identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0480] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0481] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0482] (i) an amino acid substitution at position 4 according to the numbering of SEQ ID NO: 2,

[0483] (ii) an amino acid substitution at one or more, preferably two or more, more preferably three or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 25, 176, 186, 251 , 405, and 482 according to the numbering of SEQ ID NO: 2, and (iii) at least 80%, preferably at least 91% identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0484] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0485] Preferably, the amylase variant comprises

[0486] (i) the amino acid substitution X4G according to the numbering of SEQ ID NO: 2,

[0487] (ii) one or more, two or more, three or more, four or more, five or more, or all of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2,

[0488] (iii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0489] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 ,

[0490] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0491] Preferably, the amylase variant comprises

[0492] (i) the amino acid substitution X4G according to the numbering of SEQ ID NO: 2, (ii) one or more, two or more, three or more, four or more, five or more, or all of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2,

[0493] (iii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0494] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 ,

[0495] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0496] Preferably, the amylase variant comprises

[0497] (i) a combination of amino acid substitutions selected from the group consisting of (according to the numbering of SEQ ID NO: 2):

[0498] X4Q+X25H+X176K+X186E, X4Q+X25H+X176K+X186E+X251 E, X4Q+X25H+X176K+X186E+X405M, X4Q+X25H+X176K+X186E+X482W, X4Q+X25H+X176K+X186E+X251 E+X405M, X4Q+X25H+X176K+X186E+X251 E+X482W, X4Q+X25H+X176K+X186E+X405M+X482W, and X4Q+X25H+X176K+X186E+X251 E+X405M+X482W,

[0499] (ii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0500] (iii) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0501] Preferably, the amylase variant comprises

[0502] (i) the amino acid substitution X4G according to the numbering of SEQ ID NO: 2,

[0503] (ii) one or more, two or more, three or more, four or more, five or more, or all of the amino acid substitutions selected from the group consisting of X25H, X176K, X186E, X251 E, X405M, and X482W according to the numbering of SEQ ID NO: 2,

[0504] (iii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0505] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 ,

[0506] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2), and

[0507] (v) wherein the amylase variant exhibits one or more improved property, preferably relative to said parent amylase, preferably relative to the parent amylase set forth in SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably the amylase variant has an increase in stability, thermostability, storage stability, storage stability in a detergent composition, wash performance, wash performance in a laundry detergent, and / or wash performance in a dish wash detergent, preferably, the improved property is improved stability, preferably wherein said improved property is expressed as an Improvement Factor (IF) of >1.0 and wherein preferably the Improvement Factor is equal or greater than 1.1 , preferably, equal or greater than 1.2, more preferably, equal or greater than 1.3.

[0508] Particularly preferred, the amylase variant comprises

[0509] (i) a combination of amino acid substitutions selected from the group consisting of (according to the numbering of SEQ ID NO: 2):

[0510] X4Q+X176K+X186E, X4Q+X25H+X176K+X186E, X4Q+X25H+X176K+X186E+X251 E, X4Q+X25H+X176K+X186E+X405M, X4Q+X25H+X176K+X186E+X482W, X4Q+X25H+X176K+X186E+X251 E+X405M, X4Q+X25H+X176K+X186E+X251 E+X482W, X4Q+X25H+X176K+X186E+X405M+X482W, and X4Q+X25H+X176K+X186E+X251 E+X405M+X482W,

[0511] (ii) at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 , and

[0512] (iii) a deletion of two amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0513] Especially preferred is an amylase variant comprising

[0514] (i) the combination of amino acid substitutions (according to the numbering of SEQ ID NO: 2): X4Q+X25H+X176K+X186E+X251 E+X405M+X482W,

[0515] (ii) at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 , and (iii) a deletion of two amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0516] Most preferred is an amylase variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 1 with the amino acid alterations

[0517] X4Q+X25H+X176K+X186E+X251 E+X405M+X482W according to the numbering of SEQ ID NO: 2.

[0518] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0519] (i) an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2,

[0520] (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 116, 176, 181 , 186, 195, 206, 225, 320, and 482 according to the numbering of SEQ ID NO: 2,

[0521] (iii) at least 60%, preferably at least 91 % identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0522] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0523] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0524] (i) an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2,

[0525] (ii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 116, 176, 181 , 186, 195, 206, 225, 320, and 482 according to the numbering of SEQ ID NO: 2, (iii) at least 80%, preferably at least 91% identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably wherein the parent amylase of the amylase variant is an amylase according to SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0526] (iv) said amylase variant invention comprises a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0527] Preferably, the amylase variant comprises

[0528] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0529] (ii) one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2,

[0530] (iii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0531] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0532] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2). Preferably, the amylase variant comprises

[0533] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0534] (ii) one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2,

[0535] (iii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0536] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0537] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0538] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0539] (i) an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2,

[0540] (ii) an amino acid substitution at either position 195 or 206 according to the numbering of SEQ ID NO: 2,

[0541] (iii) an amino acid substitution at one or more, preferably two or more, amino acid positions corresponding to amino acid positions selected from the group consisting of 116, 176, 181 , 186, 225, 320, and 482 according to the numbering of SEQ ID NO: 2,

[0542] (iv) at least 60%, preferably at least 91% identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and (v) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0543] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0544] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0545] (ii) the amino acid substitution eitherX195F or X206Y according to the numbering of SEQ ID NO: 2,

[0546] (iii) one or more, two or more, three or more, four or more, five or more, six or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2,

[0547] (iv) at least 60%, preferably at least 91% identity, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, or in any of SEQ ID NO: 3-15, preferably with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0548] (v) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0549] Preferably, the present invention is directed to an amylase variant of a parent amylase, wherein said variant comprises

[0550] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0551] (ii) the amino acid substitution eitherX195F or X206Y according to the numbering of SEQ ID NO: 2,

[0552] (iii) one or more, two or more, three or more, four or more, five or more, six or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2,

[0553] (iv) at least 60%, preferably at least 91% identity, but less than 100% sequence identity with SEQ ID NO: 1 , and (v) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0554] Preferably, the amylase variant comprises

[0555] (i) a combination of amino acid substitutions selected from the group consisting of (according to the numbering of SEQ ID NO: 2):

[0556] X25H+X176K+X186E, X25H+X176K+X186E+X195F, X25H+X176K+X186E+X206Y, X25H+X116K+X181 T+X206Y+X225A+X320K, X25H+X116K+X176K+X181T+X206Y+X225A+X320K, X25H+X116K+X181 T+X186E+X206Y+X225A+X320K, X25H+X116K+X181T+X206Y+X225A+X320K+X482W,

[0557] X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K,

[0558] X25H+X116K+X176K+X181 T+X206Y+X225A+X320K+X482W, X25H+X116K+X181 T+X186E+X206Y+X225A+X320K+X482W, X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K+X482W, X25H+X116K+X181 T+X195F+X225A+X320K,

[0559] X25H+X116K+X176K+X181 T+X195F+X225A+X320K,

[0560] X25H+X116K+X181T+X186E+X195F+X225A+X320K,

[0561] X25H+X116K+X181 T+X195F+X225A+X320K+X482W,

[0562] X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K,

[0563] X25H+X116K+X176K+X181 T+X195F+X225A+X320K+X482W, X25H+X116K+X181T+X186E+X195F+X225A+X320K+X482W, and X25H+X116K+X176K+X181T+X186E+X195F+X225A+X320K+X482W,

[0564] (ii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0565] (iii) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0566] Preferably, the amylase variant comprises

[0567] (i) a combination of amino acid substitutions selected from the group consisting of (according to the numbering of SEQ ID NO: 2):

[0568] X25H+X176K+X186E+X195F,

[0569] X25H+X116K+X181 T+X195F+X225A+X320K,

[0570] X25H+X116K+X176K+X181 T+X195F+X225A+X320K, X25H+X116K+X181T+X186E+X195F+X225A+X320K, X25H+X116K+X181 T+X195F+X225A+X320K+X482W, X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K, X25H+X116K+X176K+X181 T+X195F+X225A+X320K+X482W, X25H+X116K+X181T+X186E+X195F+X225A+X320K+X482W, and X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K+X482W,

[0571] (ii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0572] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0573] (iii) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0574] Preferably, the amylase variant comprises

[0575] (i) a combination of amino acid substitutions selected from the group consisting of (according to the numbering of SEQ ID NO: 2):

[0576] X25H+X176K+X186E+X206Y,

[0577] X25H+X116K+X181 T+X206Y+X225A+X320K,

[0578] X25H+X116K+X176K+X181T+X206Y+X225A+X320K, X25H+X116K+X181 T+X186E+X206Y+X225A+X320K, X25H+X116K+X181T+X206Y+X225A+X320K+X482W, X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K, X25H+X116K+X176K+X181 T+X206Y+X225A+X320K+X482W, X25H+X116K+X181T+X186E+X206Y+X225A+X320K+X482W, and X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K+X482W,

[0579] (ii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0580] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , and

[0581] (iii) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0582] Preferably, the amylase variant comprises

[0583] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2, (ii) one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2,

[0584] (iii) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least

[0585] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 ,

[0586] (iv) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2), and

[0587] (v) wherein the amylase variant exhibits one or more improved property, preferably relative to said parent amylase, preferably relative to the parent amylase set forth in SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably the amylase variant has an increase in stability, thermostability, storage stability, storage stability in a detergent composition, wash performance, wash performance in a laundry detergent, and / or wash performance in a dish wash detergent, preferably, the improved property is improved stability, preferably storage stability in a detergent composition, preferably wherein said improved property is expressed as an Improvement Factor (IF) of >1.0 and wherein preferably the Improvement Factor is equal or greater than 1.1 , preferably, equal or greater than 1.2, more preferably, equal or greater than 1.3.

[0588] Preferably, the amylase variant comprises

[0589] (i) the amino acid substitution X25H according to the numbering of SEQ ID NO: 2,

[0590] (ii) the amino acid substitution eitherX195F or X206Y according to the numbering of SEQ ID NO: 2, (iii) one or more, two or more, three or more, four or more, five or more, six or more, or all of the amino acid substitutions selected from the group consisting of X116K, X176K, X181T, X186E, X225A, X320K, and X482W according to the numbering of SEQ ID NO: 2,

[0591] (iv) at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least

[0592] 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 ,

[0593] (v) a deletion of one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184 corresponding to the numbering of SEQ ID NO: 2, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2), and

[0594] (vi) wherein the amylase variant exhibits one or more improved property, preferably relative to said parent amylase, preferably relative to the parent amylase set forth in SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1 , preferably the amylase variant has an increase in stability, thermostability, storage stability, storage stability in a detergent composition, wash performance, wash performance in a laundry detergent, and / or wash performance in a dish wash detergent, preferably, the improved property is improved stability, preferably wherein said improved property is expressed as an Improvement Factor (IF) of >1.0 and wherein preferably the Improvement Factor is equal or greater than 1.1 , preferably, equal or greater than 1.2, more preferably, equal or greater than 1.3.

[0595] Particularly preferred, the amylase variant comprises

[0596] (i) a combination of amino acid substitutions selected from the group consisting of (according to the numbering of SEQ ID NO: 2): X25H+X176K+X186E, X25H+X176K+X186E+X195F, X25H+X176K+X186E+X206Y,

[0597] X25H+X116K+X181 T+X206Y+X225A+X320K, X25H+X116K+X176K+X181T+X206Y+X225A+X320K,

[0598] X25H+X116K+X181 T+X186E+X206Y+X225A+X320K,

[0599] X25H+X116K+X181T+X206Y+X225A+X320K+X482W,

[0600] X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K, X25H+X116K+X176K+X181 T+X206Y+X225A+X320K+X482W, X25H+X116K+X181 T+X186E+X206Y+X225A+X320K+X482W, X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K+X482W, X25H+X116K+X181 T+X195F+X225A+X320K,

[0601] X25H+X116K+X176K+X181 T+X195F+X225A+X320K,

[0602] X25H+X116K+X181T+X186E+X195F+X225A+X320K,

[0603] X25H+X116K+X181 T+X195F+X225A+X320K+X482W,

[0604] X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K, X25H+X116K+X176K+X181 T+X195F+X225A+X320K+X482W, X25H+X116K+X181T+X186E+X195F+X225A+X320K+X482W, and X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K+X482W,

[0605] (ii) at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 , and

[0606] (iii) a deletion of two amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0607] Especially preferred is an amylase variant comprising

[0608] (i) the combination of amino acid substitutions (according to the numbering of SEQ ID NO: 2): X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K+X482W,

[0609] X25H+X116K+X176K+X181T+X186E+X206Y+X225A+X320K, or

[0610] X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K+X482 W, preferably X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K+X482W,

[0611] (ii) at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 , and (iii) a deletion of two amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably the deletion D183* and G184* (according to the numbering of SEQ ID NO: 2).

[0612] Most preferred is an amylase variant comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 1 with the amino acid alterations

[0613] X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K+X482W,

[0614] X25H+X116K+X176K+X181T+X186E+X206Y+X225A+X320K, or

[0615] X25H+X116K+X176K+X181 T+X186E+X206Y+X225A+X320K+X482 W,

[0616] X25H+X116K+X176K+X181 T+X186E+X195F+X225A+X320K+X482W according to the numbering of SEQ ID NO: 2.

[0617] In one embodiment the amylase variant of the enzyme composition comprises

[0618] (i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 183, 243, 266 and 475 according to the numbering of SEQ ID NO: 9 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 9, or

[0619] (ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 38, 126, 129, 153, 180, 187, 199, 203, 241 , 362, 377, 458, 459, 460, 476 and 477 according to the numbering of SEQ ID NO: 7 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 7, or

[0620] (iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 7, 51 , 52, 54, 109, 140, 195, 206, 243, 260, 280, 284, 304, 391 , 476 and 477 according to the numbering of SEQ ID NO: 3 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 3, or

[0621] (iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 458 and 471 according to the numbering of SEQ ID NO: 13 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 13, or

[0622] (v) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 149, 167, 172, 174, 182, 195, 202, 206, 246, 257, 295, 299, 320, 339, 345, 391 , 458, 471 , 473 and 476 according to the numbering of SEQ ID NO: 15 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 15, or

[0623] (vi) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 405, 421 ,422,428, 458 and 471 according to the numbering of SEQ ID NO: 4 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 4, or

[0624] (vii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 120, 134, 140, 167, 169, 172, 173, 174, 182, 183, 184, 195, 202, 206, 246, 255, 257, 260, 265, 295, 299, 304, 320, 339, 345, 391 , 395, 410, 422, 429, 444, 451 , 458, 473, 474 and 476 according to the numbering of SEQ ID NO: 5; and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 5.

[0625] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 9, and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 183, 243, 266 and 475, more preferably selected from X183S, X243Q, X266Y, and X475K (according to the numbering of SEQ ID NO: 9).

[0626] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 9, and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 183, 243, 266 and 475, more preferable G183S, S243Q, F266Y, G475K (according to the numbering of SEQ ID NO: 9).

[0627] In one embodiment, the amylase variant comprises an amino acid sequence whichhas at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 9, comprising a two amino acid deletion in the region of R180, G181 , T182, G183 with optionally a truncation of the C-terminal part (amino acids 485-583) and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 183, 243, 266 and 475, more preferable all of G183S, S243Q, F266Y, and G475K (according to the numbering of SEQ ID NO: 9).

[0628] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 7 and an amino acid mutation at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 38, 126, 129, 153, 180, 187, 199, 203, 241 , 362, 377, 458, 459, 460, 476 and 477, preferably one or more, preferably all, of the mutations selcted from the group consisting of X38N, X126Y, X129I, X153W, X180D / H, X187P, X199L, X203Y, X241Q, X362A, X377Y, X458N, X459S, X460T, X476K and X477E; more preferable all of X38N, X126Y, X129I, X153W, X178*, X179*, X180D, X187P, X203Y, X476K, and X477E or all of X178*, X179*, X187P, X203Y X458N, X459S, X460T, and X476K in combination (according to the numbering of SEQ ID NO: 7).

[0629] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 7 and an amino acid mutation at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 38, 126, 129, 153, 180, 187, 199, 203, 241 , 362, 377, 458, 459, 460, 476 and 477, preferably one or more, preferably all, of the mutations selcted from the group consisting of T38N, N126Y, T129I, F153W, T180D / H, E187P, M199L, I203Y, S241Q, S362A, R377Y, R458N, T459S, D460T, G476K and G477E; more preferable all of T38N, N126Y, T129I, F153W, R178*, G179*, T180D, E187P, I203Y, G476K, and G477E or all of R178*, G179*, E187P, I203Y R458N, T459S, D460T, and G476K in combination (according to the numbering of SEQ ID NO: 7).

[0630] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 3, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 7, 51 , 52, 54, 109, 140, 195, 206, 243, 260, 280, 284, 304, 391 , 476 and 477; preferably one or more, preferably all, of the mutations selcted from the group consisting of X1*, X7A, X511, X52Q, X54K, X109A, X140Y, X195F, X206Y, X243F, X260G, X280S, X284F / D / R, X304R, X391A, X476E / K and X477R / K / E, preferably all of X1*, X7A, X511, X52Q, X54K, X109A, X140Y, X195F, X206Y, X243F, X260G, X280S, X284F / D / R, X304R, X391A, X476E / K and X477R / K / E in combination (according to the numbering of SEQ ID NO: 2). In one embodiment, the amylase variant comprises an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 3, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 7, 51 , 52, 54, 109, 140, 195, 206, 243, 260, 280, 284, 304, 391 , 476 and 477; preferably one or more, preferably all of the mutations selcted from the group consisting of H1*, G7A, T511, S52Q, N54K, G109A, W140Y, N195F, V206Y, Y243F, E260G, N280S, W284F / D / R, G304R, E391A, G476E / K and G477R / K / E, preferably all of H1*. G7A, T511, S52Q, N54K, G109A, W140Y, N195F, V206Y, Y243F, E260G, N280S, W284F / D / R, G304R, E391A, G476E / K and G477R / K / E in combination (according to the numbering of SEQ ID NO: 2).

[0631] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 13, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 458 and 471 ; preferably one or more, preferably all, of the mutations selcted from the group consisting of X9I / L, X118K, X149A, X182T, X186A, X195F, X202L, X246V, X257I, X295F, X299Y, X320K, X323T, X339S, X345R, X458K and X471 E; more preferred all of the mutations X118K, X183*, X184*, X195F, X320K and X458K or all of X9L, X118K, X149A, X182T, X183*, X184*, X186A, X195F, X202L, X257I, X295F, X299Y, X320K, X323T, X339S, X345R and X458K in combination (according to the numbering of SEQ ID NO: 13).

[0632] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 13, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 458 and 471 ; preferably one or more, preferably all of the mutations selcted from the group consisting of M9I / L, R118K, G149A, G182T, G186A, N195F, M202L, T246V, T257I, Y295F, N299Y, R320K, M323T, A339S, E345R, R458K and N471 E; more preferred all of the mutations R118K, D183*, G184*, N195F, R320K and R458K or M9L, R118K, G149A, G182T, D183*, G184*, G186A, N195F, M202L, T257I, Y295F, N299Y, R320K, M323T, A339S, E345R and R458K in combination (according to the numbering of SEQ ID NO: 13).

[0633] Amylases with substitutions as described above are shown for instance in SEQ ID NO: 14.

[0634] Thus, in one embodiment, the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 14.

[0635] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 15, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 149, 167, 172, 174, 182, 195, 202, 206, 246, 257, 295, 299, 320, 339, 345, 391 , 458, 471 , 473 and 476; preferably one or more, preferably all of the mutations selcted from the group consisting of X1A, X54S, X56T, X72R, X109A, X113Q, X116Q, X149A, X167F, X172G, X174S, X182T, X195F, X202L, X206L / Y, X246V, X257I, X295F, X299Y, X320K, X339S, X345R.XK391A, X458K, X471 E, X473R and X476K; preferably all of X1A, X54S, X56T, X72R, X109A, X113Q, X116Q, X149A, X167F, X172G, X174S, X182T, X195F, X202L, X206L / Y, X246V, X257I, X295F, X299Y, X320K, X339S, X345R, X391A, X458K, X471 E, X473R and X476K in combination (according to the numbering of SEQ ID NO: 15).

[0636] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 15, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 149, 167, 172, 174, 182, 195, 202, 206, 246, 257, 295, 299, 320, 339, 345, 391 , 458, 471 , 473 and 476; preferably one or more, preferably all, of the mutations selcted from the group consisting of H1A, N54S, V56T, K72R, G109A, F113Q, R116Q, G149A, W167F, Q172G, A174S, G182T, N195F, M202L, V206L / Y, M246V, T257I, Y295F, Q299Y, R320K, A339S, Q345R, K391A, R458K, H471 E, F473R and G476K; preferably all of H1A, N54S, V56T, K72R, G109A, F113Q, R116Q, G149A, W167F, Q172G, A174S, G182T, N195F, M202L, V206L / Y, M246V, T257I, Y295F, Q299Y, R320K, A339S, Q345R, K391A, R458K, H471 E, F473R and G476K in combination (according to the numbering of SEQ ID NO: 15).

[0637] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 4, comprising a two amino acid deletion in the region of R181 , G182, H183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 405, 421 ,422,428, 458 and 471 ; preferably one or more, preferably all of the mutations selcted from the group consisting of X9I / L, X118K, X149A, X182T, X186A, X195F, X202L, X246V, X257I, X295F, X299Y, X320K, X323T, X339S, X345R, X405L, X421 H, X422P, X428T, X458K and X471 E, more preferred all the mutations X183*, X184*, X405L, X421 H, X422P, and X428T in combination (according to the numbering of SEQ ID NO: 4).

[0638] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 4, comprising a two amino acid deletion in the region of R181 , G182, H183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 405, 421 ,422,428, 458 and 471 ; preferably one or more, preferably all, of the mutations selcted from the group consisting of M9I / L, R118K, G149A, G182T, G186A, N195F, M202L, T246V, T257I, Y295F, N299Y, R320K, M323T, A339S, E345R, I405L, A421 H, A422P, A428T, R458K and N471 E, more preferred all the mutations H183*, G184*, I405L, A421 H, A422P, and A428T in combination (according to the numbering of SEQ ID NO: 4).

[0639] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 60%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 5, and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 120, 134, 140, 167, 169, 172, 173, 174, 182, 183, 184, 195, 202, 206, 246, 255, 257, 260, 265, 295, 299, 304, 320, 339, 345, 391 , 395, 410, 422, 429, 444, 451 , 458, 473, 474 and 476; preferably one or more, preferably all, of the mutations selcted from the group consisting of X1*, X54S, X56T, X72R, X109A, X113Q, X116H, X116Q, X120L, X134E, X140Y, X167F, X169E, X172E, X172G, X172K, X172N, X172R, X173P, X173V, X174*, X174S, X174K, X182T, X195F, X202L, X206L, X206Y, X246V, X255A, X257I, X260G, X265G, X295F, X299Y, X304R, X320A, X320K, X339S, X345R, X391A, X395P, X410I, X422P, X429I, X444Q, X451W, X458K, X473R, X474V and X476K more preferred one or more, preferably all, of the modifications selected from the group consisting of X1*, X54S, X56T, X72R, X109A, X113Q, X116Q, X167F, X172G, X174S, X182*, X183*, X184T, X195F, X206L, X391A, X473R and X476K, preferably all of X1*, X54S, X56T, X72R, X109A, X113Q, X116Q, X167F, X172G, X174S, X182*, X183*, X184T, X195F, X206L, X391A, X473R and X476K in combination (according to the numbering of SEQ ID NO: 5).

[0640] In one embodiment, the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 5, comprising a two amino acid deletion in the region of R181 , G182, D183, G184 and further an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 120, 134, 140, 167, 169, 172, 173, 174, 182, 183, 184, 195, 202, 206, 246, 255, 257, 260, 265, 295, 299, 304, 320, 339, 345, 391 , 395, 410, 422, 429, 444, 451 , 458, 473, 474 and 476; preferably one or more, preferably all, of the mutations selcted from the group consisting of H1*, N54S, V56T, K72R, G109A, F113Q, R116H, R116Q, V120L, T134E, W140Y, W167F, Q169E, Q172E, Q172G, Q172K, Q172N, Q172R, L173P, L173V, A174*, A174S, A174K, G182T, N195F, M202L, V206L, V206Y, M246V, G255A, T257I, N260G, A265G, Y295F, Q299Y, S304R, R320A, R320K, A339S, Q345R, K391A, Q395P, V410I, A422P, V429I, T444Q, F451W, R458K, P473R, C474V and G476K more preferred one or more, preferably all, of the modifications selected from the group consisting of H1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K, preferably all of H1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K in combination (according to the numbering of SEQ ID NO: 5).

[0641] Amylases with substitutions as described above are shown for instance in SEQ ID NO: 6.

[0642] Thus, in one embodiment, the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91%, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 6.

[0643] Preferably, the composition further comprises an amylase variant comprising a) the amino acid substitution X25H and one or more amino acid substitutions selected from the group consisting of X4Q, X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X251 E, X320K, X405M, and X482W according to the numbering of SEQ ID NO: 2, b) a deletion at one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably of two or more, most preferably of two, amino acids corresponding to positions selected from the group consisting of R181 , G182, D183, and G184, preferably D183* and G184*, wherein the numbering is according to the amino acid sequence set forth in SEQ ID NO: 2, and c) wherein the amylase variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1.

[0644] Alternatively preferred, the composition further comprises an amylase variant and wherein the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 5, and an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 120, 134, 140, 167, 169, 172, 173, 174, 182, 183, 184, 195, 202, 206, 246, 255, 257, 260, 265, 295, 299, 304, 320, 339, 345, 391 , 395, 410, 422, 429, 444, 451 , 458, 473, 474 and 476; preferably the mutations X1*, X54S, X56T, X72R, X109A, X113Q, X116H, X116Q, X120L, X134E, X140Y, X167F, X169E, X172E, X172G, X172K, X172N, X172R, X173P, X173V, X174*, X174S, X174K, X182T, X195F, X202L, X206L, X206Y, X246V, X255A, X257I, X260G, X265G, X295F, X299Y, X304R, X320A, X320K, X339S, X345R, X391A, X395P, X410I, X422P, X429I, X444Q, X451W, X458K, X473R, X474V and X476K, more preferred one or more of the modifications selected from the group consisting of X1*, X54S, X56T, X72R, X109A, X113Q, X116Q, X167F, X172G, X174S, X182*, X183*, X184T, X195F, X206L, X391A, X473R and X476K (according to the numbering of SEQ ID NO: 5), preferably all modfications in combination, most preferred the modificiations H1*, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K in combination. Hence, in another preferred alternative embodiment, the composition further comprises an amylase variant and wherein the amylase variant comprises an amino acid sequence which has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91 .5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO: 6.

[0645] Preferably, the composition comprises a protease, a mannanase, a cellulase, and an amylase wherein a. the protease is a protease variant comprising

[0646] (i) the amino acid substitution X101 E according to the numbering of SEQ ID NO: 17, and

[0647] (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least

[0648] 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least

[0649] 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least

[0650] 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least

[0651] 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least

[0652] 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to SEQ ID NO: 16, b. the mannanase is a mannanase variant comprising

[0653] (i) at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight or all amino acid substitutions X89V, X96D, X119H, X264Q, X289M, X312Y, X348N, X349G, and X352G according to the numbering of SEQ ID NO: 35, and (ii) an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least

[0654] 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least

[0655] 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least

[0656] 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least

[0657] 98.5%, at least 99%, or at least 99.5%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and c. the cellulase is a cellulase variant comprising an amino acid sequence which is at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least

[0658] 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least

[0659] 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least

[0660] 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least

[0661] 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, at least 99.5%, or 100% identical to SEQ ID NO: 42, wherein the amylase is an amylase variant comprising a) the amino acid substitution X25H and one or more amino acid substitutions selected from the group consisting of X4Q, X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X251 E, X320K, X405M, and X482W according to the numbering of SEQ ID NO: 2, b) a deletion at one or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of two or more amino acids corresponding to positions selected from the group consisting of 181 , 182, 183 and 184, preferably a deletion of amino acids corresponding to positions 181 and 182, 182 and 183, or 183 and 184, preferably of two or more, most preferably of two, amino acids corresponding to positions selected from the group consisting of R181 , G182, D183, and G184, preferably D183* and G184*, wherein the numbering is according to the amino acid sequence set forth in SEQ ID NO: 2, and c) wherein the amylase variant has at least 85%, at least 85.5%, at least 86%, at least 86.5%, at least 87%, at least 87.5%, at least 88%, at least 88.5%, at least 89%, at least 89.5%, at least 90%, at least 90.5%, at least 91 %, at least 91.5%, at least 92%, at least 92.5%, at least 93%, at least 93.5%, at least 94%, at least 94.5%, at least 95%, at least 95.5%, at least 96%, at least 96.5%, at least 97%, at least 97.5%, at least 98%, at least 98.5%, at least 99%, or at least 99.5%, but less than 100% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 1. Lipases

[0662] “Lipases”, “lipolytic enzyme”, “lipid esterase”, all refer to an enzyme of EC class 3.1.1 (“carboxylic ester hydrolase”). Lipase means active protein having lipase activity (or lipolytic activity; triacylglycerol lipase, EC 3.1.1.3), cutinase activity (EC 3.1.1.74; enzymes having cutinase activity may be called cutinase herein), sterol esterase activity (EC 3.1.1.13) and / or wax-ester hydrolase activity (EC 3.1 .1 .50). Lipases include those of bacterial or fungal origin.

[0663] In one aspect of the invention, a suitable lipase is selected from the following: lipases from Hu- micola (synonym Thermomyces), e.g. from H. lanuginosa (T. lanuginosus) as described in EP 258068, EP 305216, WO 92 / 05249 and WO 2009 / 109500 or from H. insolens as described in WO 96 / 13580; lipases derived from Rhizomucor miehei as described in WO 92 / 05249; lipase from strains of Pseudomonas (some of these now renamed to Burkholderia), e.g. from P. alcali- genes or P. pseudoalcaligenes (EP 218272, WO 94 / 25578, WO 95 / 30744, WO 95 / 35381 , WO 96 / 00292), P. cepacia (EP 331376), P. stutzeri (GB 1372034), P. fluorescens, Pseudomonas sp. strain SD705 (WO 95 / 06720 and WO 96 / 27002), P. wisconsinensis (WO 96 / 12012), Pseudomonas mendocina (\NO 95 / 14783), P. glumae (WO 95 / 35381 , WO 96 / 00292); lipase from Streptomyces griseus (WO 2011 / 150157) and S. pristinaespiralis (WO 2012 / 137147), GDSL-type Streptomyces lipases (WO 2010 / 065455); lipase from Thermo- bifida fusca as disclosed in WO 2011 / 084412; lipase from Geobacillus stearothermophilus as disclosed in WO 2011 / 084417; Bacillus lipases, e.g. as disclosed in WO 00 / 60063, lipases from B. subtilis as disclosed in Dartois et al. (1992), Biochemica et Biophysica Acta, 1131 , 253- 360 or WO 2011 / 084599, B. stearothermophilus (JP S64-074992) or B. pumilus (WO 91 / 16422); lipase from Candida antarctica as disclosed in WO 94 / 01541 ; cutinase from Pseudomonas mendocina (US 5389536, WO 88 / 09367); cutinase from Magnaporthe grisea (WO 2010 / 107560); cutinase from Fusarum solani pisi as disclosed in WO 90 / 09446, WO 00 / 34450 and WO 01 / 92502; and cutinase from Humicola lanuginosa as disclosed in WO 00 / 34450 and WO 01 / 92502.

[0664] Such suitable lipase variants are e.g. those which are developed by methods as disclosed in WO 95 / 22615, WO 97 / 04079, WO 97 / 07202, WO 00 / 60063, WO 2007 / 087508, EP 407225 and EP 260105. Commercially available lipase enzymes include but are not limited to those sold under the trade names Lipolase™, Lipex™, Lipolex™ and Lipoclean™ (Novozymes A / S), Lumafast (originally from Genencor), Preferenz L (DuPont), Biotouch LL100 (AB Enzymes), and Lipomax (Gist- Brocades / now DSM).

[0665] In one embodiment, lipase is selected from fungal triacylglycerol lipase (EC class 3.1.1.3). Fungal triacylglycerol lipase may be selected from lipases of Thermomyces lanuginosus. In one embodiment, the Thermomyces lanuginosa lipase is selected from triacylglycerol lipase according to amino acids 1-269 of SEQ ID NO: 2 of US5869438 and variants thereof having lipolytic activity.

[0666] Thermomyces lanuginosa lipase may be selected from variants having lipolytic activity which are at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical when compared to the full length polypeptide sequence of amino acids 1-269 of SEQ ID NO: 2 of US5869438.

[0667] Thermomyces lanuginosa lipase may be selected from variants having lipolytic activity comprising conservative mutations only, which do not pertain the functional domain of amino acids 1- 269 of SEQ ID NO: 2 of US5869438. Lipase variants of this embodiment having lipolytic activity may be at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar when compared to the full-length polypeptide sequence of amino acids 1-269 of SEQ ID NO: 2 of US5869438.

[0668] Thermomyces lanuginosa lipase may be selected from variants having lipolytic activity comprising the following amino acid substitutions when compared to amino acids 1-269 of SEQ ID NO: 2 of US5869438: T231 R and N233R. Said lipase variants may further comprise one or more of the following amino acid exchanges when compared to amino acids 1-269 of SEQ ID NO: 2 of US5869438: Q4V, V60S, A150G, L227G, P256K.

[0669] Thermomyces lanuginosa lipase may be selected from variants having lipolytic activity comprising the amino acid substitutions T231 R, N233R, Q4V, V60S, A150G, L227G, P256K within the polypeptide sequence of amino acids 1-269 of SEQ ID NO: 2 of US5869438 and are at least 95%, at least 96%, or at least 97% similar when compared to the full length polypeptide sequence of amino acids 1-269 of SEQ ID NO: 2 of US5869438.

[0670] Thermomyces lanuginosa lipase may be selected from variants having lipolytic activity comprising the amino acid substitutions T231 R and N233R within amino acids 1-269 of SEQ ID NO: 2 of US5869438 and are at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar when compared to the full length polypeptide sequence of amino acids 1-269 of SEQ ID NO: 2 of US5869438.

[0671] Thermomyces lanuginosa lipase may be a variant of amino acids 1-269 of SEQ ID NO: 2 of US5869438 having lipolytic activity, wherein the variant of amino acids 1-269 of SEQ ID NO: 2 of US5869438 is characterized in containing the amino acid substitutions T231 R and N233R. Thermomyces lanuginosa lipase may be selected from variants having lipolytic activity preferably comprising at least one, preferably more than one, more preferably all of the following substitutions N11 K, A18K, G23K, K24A, V77I, D130A, V154I, V187T, T189Q within the polypeptide sequence of amino acids 1-269 of SEQ ID NO: 1 of WO2015 / 010009 and are at least 95%, at least 96%, or at least 97% similar when compared to the full length polypeptide sequence of amino acids 1-269 of SEQ ID NO: 1 of WO2015 / 010009.

[0672] Methods of obtaining the enzyme and making the enzyme composition

[0673] Another embodiment of the present invention is a method of making the enzyme composition comprising a protease, a mannanase and / or a cellulase as described herein, preferably comprising the step of a) obtaining a sequence of a variant of a protease, a mannanase and / or a cellulase as described herein, b) producing said variant of a protease, a mannanase or a cellulase using the sequence obtained under a), as described herein, and c) mixing two or more enzymes selected from the group consisting of protease, mannanase, and cellulase as described herein in one or more steps.

[0674] Ways of obtaining a specific enzyme variant are known to the skilled person. Ways of introducing amino acid alterations as described, e.g., a substitution or a deletion, into protein sequences are well known in the art. The variants of the enzymes as described herein may be prepared using any mutagenesis procedure known in the art, such as site-directed mutagenesis, synthetic gene construction, semi-synthetic gene construction, random mutagenesis, shuffling, etc. Site- directed mutagenesis is a technique in which one or more (several) mutations are created at one or more defined sites in a polynucleotide. Site-directed mutagenesis can be accomplished in vitro by PCR involving the use of oligonucleotide primers containing the desired mutation. Site-directed mutagenesis can also be performed in vitro by cassette mutagenesis involving the cleavage by a restriction enzyme at a site in the plasmid comprising a polynucleotide encoding the nucleotide to be mutated and subsequent ligation of an oligonucleotide containing the mutation in the polynucleotide. Usually, the restriction enzyme that digests the plasmid and the oligonucleotide is the same, permitting sticky ends of the plasmid and insert to ligate to one another. See, e.g., Scherer and Davis, 1979, Proc. Natl. Acad. Sei. USA 76: 4949-4955; and Barton et al., 1990, Nucleic Acids Res. 18: 7349-4966. Site-directed mutagenesis can also be accomplished in vivo by methods known in the art. See, e.g., U.S. Patent Application Publication No. 2004 / 0171154; Storici etal., 2001 , Nature Biotechnol. 19: 773-776; Kren et al., 1998, Nat. Med. 4: 285-290; and Calissano and Macino, 1996, Fungal Genet. Newslett. 43: 15-16. Any site-directed mutagenesis procedure can be used in the present invention. There are many commercial kits available that can be used to prepare variants.

[0675] Synthetic gene construction entails in vitro synthesis of a designed polynucleotide molecule to encode a polypeptide of interest. Gene synthesis can be performed utilizing a number of techniques, such as the multiplex microchip-based technology described by Tian et al. (2004, Nature 432: 1050-1054) and similar technologies wherein oligonucleotides are synthesized and assembled upon photo-programable microfluidic chips.

[0676] Single or multiple amino acid substitutions, deletions, and / or insertions can be made and tested using known methods of mutagenesis, recombination, and / or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241 : 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95 / 17413; or WO 95 / 22625. Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et al., 1991 , Biochemistry 30: 10832-10837; U.S. Patent No. 5,223,409; WO 92 / 06204) and region-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Ner et al., 1988, DNA 7: 127).

[0677] Mutagenesis / shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness et al., 1999, Nature Biotechnology 17: 893-896). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.

[0678] Semi-synthetic gene construction is accomplished by combining aspects of synthetic gene construction, and / or site-directed mutagenesis, and / or random mutagenesis, and / or shuffling. Semisynthetic construction is typified by a process utilizing polynucleotide fragments that are synthesized, in combination with PCR techniques. Defined regions of genes may thus be synthesized de novo, while other regions may be amplified using site-specific mutagenic primers, while yet other regions may be subjected to error-prone PCR or non-error prone PCR amplification. Polynucleotide subsequences may then be shuffled.

[0679] The obtained enzyme can be produced in an industrial scale and subsequently purified. Industrial production of enzymes usually is done by cultivating a host cell (also called fermentation) which expresses the enzyme. Suitable host cells are described herein. A nucleic acid sequence encoding the respective enzyme described herein can be transformed into the host cell, which is subsequently cultivated under conditions suitable for the host cell to produce the enzyme. In a preferred embodiment, the enzyme is purified from the host cell.

[0680] Producing an enzyme, preferably comprises the steps of

[0681] (a) providing a host cell comprising a heterologous nucleic acid construct comprising a polynucleotide encoding the enzyme described herein by introducing the nucleic acid construct comprising the polynucleotide encoding the enzyme as described herein into the host cell;

[0682] (b) cultivating the recombinant host cell of step (a) under conditions conductive for the expression of the polynucleotide; and

[0683] (c) optionally, recovering the enzyme encoded by the polynucleotide.

[0684] Cultivation of the host cell normally takes place in a suitable nutrient medium allowing the recombinant cells to grow and express the desired protein. At the end of fermentation, the fermentation broth is collected and may be further processed, wherein the fermentation broth comprises a liquid fraction and a solid fraction. The enzyme of interest may be further purified from the fermentation broth.

[0685] The amylase, protease, mannanase and cellulase as described herein may be secreted (into the liquid fraction of the fermentation broth) or may not be secreted from the microbial cells (and therefore is comprised in the cells of the fermentation broth). Depending on this, the enzyme may be recovered from the liquid fraction of the fermentation broth or from cell lysates. Preferably, the enzyme is secreted from the cell into the fermentation broth, preferably by means of a secretion signal peptide added to the terminus of the amino acid sequence of the respective enzyme. Recovery of the enzyme can be achieved by methods known to those skilled in the art. Suitable methods for recovery of proteins from fermentation broth include but are not limited to collection, centrifugation, filtration, extraction, and precipitation. If the product of interest precipitates or crystallizes in the fermentation broth or binds at least in part to the particulate matter of the fermentation broth additional treatment steps might be needed to release the protein of interest from the biomass or to solubilize protein of interest crystals and precipitates. W00043502A1 , W02008110498 A1 , and WO2017097869A1 describe a method for recovering a protein of interest, which precipitates and / or crystallizes during fermentation, from the fermentation broth. In case the desired protein is comprised in the cells of the fermentation broth release of the product of interest from the cells might be needed. Release from the cells can be achieved for instance, but not being limited thereto, by cell lysis with techniques well known to the skilled person, e.g., lysozyme treatment, ultrasonic treatment, French press or combinations thereof.

[0686] The protease, mannanase and cellulase as described herein may be purified from the fermentation broth by methods known in the art. For example, the respective enzyme may be isolated from the fermentation broth by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The isolated polypeptide may then be further purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989). The purified polypeptide may then be concentrated by procedures known in the art including, but not limited to, ultrafiltration and evaporation, in particular, thin film evaporation.

[0687] The enzyme composition described herein may be further processed to form an enzyme composition containing preparation. Hence, also claimed herein is a preparation comprising the enzyme composition described herein and at least one additional component.

[0688] Thus, the present invention therefore also refers to a method of making a preparation comprising the steps of mixing a) an enzyme composition as described herein; and b) one or more components described herein.

[0689] The preparation can be a non-complex formulation, e.g., an enzyme composition containing formulation, or a complex formulation, e.g., a detergent composition.

[0690] In one embodiment of the present invention, the enzyme composition is formulated as an enzyme composition containing formulation, preferably a concentrated enzyme composition containing formulation. The enzyme composition containing formulation can be either solid or liquid. Protein formulations can be obtained by using techniques known in the art. For instance, without being limited thereto, solid enzyme formulations can be obtained by extrusion or granulation. Suitable extrusion and granulation techniques are known in the art and are described for instance in WO 94 / 19444 A1 and WO 97 / 43482 A1.

[0691] Liquid enzyme formulations may comprise amounts of enzyme in the range of 0.012% to 40%, 0.02% to 20%, 0.04% to 12%, 0.1 % to 8%, or preferably 0.2 to 6% by weight, all relative to the total weight of the enzyme formulation.

[0692] Preferably, the enzyme formulation comprises the enzymes of the present invention in an amount of 2-120 mg active enzymes per g of enzyme formulation, preferably 6-80 mg / g, 6-60 mg / g, or 10-40 mg / g.

[0693] In one embodiment, the enzyme composition containing formulation, in particular the liquid enzyme formulation, comprises in addition one or more additional compounds selected from the group consisting of solvent, salt, pH regulator, preservative, enzyme stabilizer, and thickening agent. Preferably, the enzyme composition containing formulation is devoid of surfactants. The solvent may be water and / or an organic solvent. Aqueous enzyme composition containing formulations of the invention may comprise water in amounts of more than about 50% by weight, more than about 60% by weight, more than about 70% by weight, or more than about 80% by weight, all relative to the total weight of the enzyme formulation. The enzyme composition containing formulations of the invention may comprise an organic solvent in amounts of more than 30%, more than 40%, more than about 50% by weight, more than about 60% by weight, more than about 70% by weight, or more than about 80% by weight, all relative to the total weight of the enzyme formulation. The organic solvent may be a water-miscible solvent. The organic solvent may be one or more selected from the group consisting of glycerol, propanediol, polypropylene glycol, and polyethylene glycol.

[0694] In one embodiment, the enzyme composition containing formulation comprises at least one preservative. Preferably, preservative means substances that are added to a liquid composition for the purpose of preservation, meaning more preferably that compounds known to have preserving features comprised in a liquid composition formed in the production process are excluded from the term preservatives. In one embodiment, the preservative is selected from the group consisting of 2-phenoxyethanol, glutaraldehyde, 2-bromo-2-nitropropane-1 ,3-diol, and formic acid in acid form or as its salt, and 4,4’-dichloro 2-hydroxydiphenylether. Usually, the liquid compositions of the invention comprise at least one preservative in amounts below 10ppm, such as in amounts ranging from 2 ppm to 5% by weight relative to the total weight of the liquid composition. Alternatively, the enzyme composition containing formulation is free from preservatives, meaning that preservatives are comprised in amounts less than 1 ppm, preferably 0 ppm. Preferably, the enzyme composition containing formulation comprises respective enzyme stabilizing systems. Preferably, the enzyme composition containing formulation described herein comprises from about 0.001 % to about 10%, from about 0.005% to about 8%, or from about 0.01 % to about 6%, by weight of the composition, of an enzyme stabilizing system. The enzyme stabilizing system can be any stabilizing system which is compatible with the enzymes of the enzyme composition. Preferably, the enzyme stabilizing system comprises at least one compound selected from the group consisting of polyols (preferably, 1 ,3-propanediol, ethylene glycol, glycerol, 1 ,2- propanediol, or sorbitol), inorganic salts (preferably, CaCI2, MgCI2, or NaCI), short chain (preferably, C1-C3) carboxylic acids or salts thereof (preferably, formic acid, formate (preferably, sodium formate), acetic acid, acetate, or lactate), borate, boric acid, boronic acids (preferably, 4-formyl phenylboronic acid (4-FPBA)), peptide aldehydes (preferably, Z-VAL-H or Z-GAY-H), peptide acetals, and peptide aldehyde hydrosulfite adducts, depending on the enzymes contained in the respective enzyme composition. Preferably, in case a protease is present the enzyme stabilizing system comprises a combination of at least two of the compounds selected from the group consisting of salts, polyols, and short chain carboxylic acids and preferably one or more of the compounds selected from the group consisting of borate, boric acid, boronic acids (preferably, 4- formyl phenylboronic acid (4-FPBA)), peptide aldehydes, peptide acetals, and peptide aldehyde hydrosulfite adducts. In case a protease is contained in the enzyme composition, it is preferred that the stabilizing system comprises a protease inhibitor, preferably selected from borate, boric acid, boronic acids (preferably, 4-FPBA), peptide aldehydes (preferably, peptide aldehydes like Z-VAL-H or Z-GAY-H), peptide acetals, and peptide aldehyde hydrosulfite adducts, preferably the protease inhibitor is a peptide aldehyde, preferably Z-VAL-H or Z-GAY-H. In one embodiment, the stabilizing system does not comprise a protease inhibitor. Preferably, the enzyme formulation is boron-free. In case an amylase and I or a protease is present the formulation may comprise a calcium salt, preferably calcium chloride.

[0695] Preferably, the liquid formulation containing the enzyme composition comprises or consists of the enzyme composition, a solvent, at least one enzyme stabilizing system, and optionally a preservative and optionally a further enzyme different from the enzymes of the enzyme composition described herein. Preferably, the amylase variant formulation is devoid of surfactants.

[0696] Thus, the present invention therefore also refers to a method for making an enzyme composition containing formulation, preferably a concentrated enzyme composition containing formulation, comprising the steps of mixing a) an enzyme composition as described herein; and b) one or more components selected from the group consisting of solvent, enzyme stabilizing system, preservative, and a further enzyme different from the enzymes of the enzyme composition described herein.

[0697] Detergent compositions

[0698] In one embodiment, the present invention is directed to the use of the enzyme composition in a detergent composition. Thus, the present invention is also directed to a detergent composition comprising the enzyme composition described herein and one or more detergent component. Thus, the present invention therefore also refers to a method for making a detergent composition comprising the steps of mixing a) an enzyme composition as described herein; and b) one or more detergent component described herein.

[0699] Further, the present invention therefore also refers to a method for making a detergent composition with improved amylase stability and / or for providing a detergent composition with improved wash performance comprising the steps of mixing a) an enzyme composition as described herein; and b) one or more detergent component described herein.

[0700] The one or more detergent component may be selected from the group consisting of additional enzymes different from the enzymes of the enzyme composition described herein, enzyme stabilizing system, surfactant, defoamer, builder, polymer, bleaching system (bleach), rheology modifier, hydrotrope, softening agent, desiccant, whitening agent, buffer, preservative, anti-cor- rosion additive, dyestuff and fragrance.

[0701] Preferably, at least one component of the detergent is selected from the group consisting of surfactant, builder, polymer, preservative, and further enzyme different from the enzymes of the enzyme composition described herein.

[0702] Preferably one or more of the detergent component, preferably the surfactant and / or the builder, is bio-degradable and / or bio-based.

[0703] Detergent components may have more than one function in the final application of a detergent composition, therefore any detergent component mentioned in the context of a specific function herein, may also have another function in the final application of a detergent composition. The function of a specific detergent component in the final application of a detergent composition usually depends on its amount within the detergent composition, i.e., the effective amount of a detergent component. Detergent components vary in type and / or amount in a detergent composition depending on the desired application such as laundering white textiles, colored textiles, and wool. The component(s) chosen further depend on physical form of a detergent composition (liquid, solid, gel, provided in pouches or as a tablet, etc.). The component(s) chosen e.g. for laundering formulations further depend on regional conventions which themselves are related to aspects like washing temperatures used, mechanics of laundry machine (vertical vs. horizontal axis machines), water consumption per wash cycle etc. and geographical characteristics like average hardness of water.

[0704] In one embodiment, a detergent composition is a formulation of more than two detergent components, wherein at least one component is effective in stain-removal, at least one component is effective in providing the optimal cleaning conditions, and at least one component is effective in maintaining the physical characteristics of the detergent.

[0705] The detergent composition can be a liquid o...

Claims

CLAIMS1. A composition comprising two or more enzymes selected from the group consisting of protease, mannanase, and cellulase, wherein a. the protease is selected fromI. a protease variant of a parent protease, wherein the protease variant comprises(i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and(ii) an amino acid sequence which is at least 60%, but less than 100% identical to any of SEQ ID NO: 16-34, preferably SEQ ID NO: 16, orII. a protease variant of a parent protease, wherein the protease variant comprises(i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 3, 4, 9, 19, 22, 43, 62, 63, 76, 87, 99, 101, 103, 104, 116, 118, 128, 129, 130, 156, 160, 167, 170, 182, 185, 188, 194, 205, 213, 217, 218, 232, 245, 256, 259, 262, and 271 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 22, or(ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 53, 76, 78, 101, 128, and 217 according to the numbering of SEQ ID NO: 17 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 17, or(iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 89, 130, 133, 144, 159, 183, 189. 217, 224, 238, 243, 252, 259, 270 and 271 according to the numbering of SEQ ID NO: 19 and an amino acid sequence which has at least 60%, but less than 100% sequence identity with SEQ ID NO: 19, or(iv) an amino acid sequence which has at least 60% sequence identity with SEQ ID NO: 22, SEQ ID NO: 21 , SEQ ID NO: 30, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 31, b. the mannanase is selected fromI. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises(i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233, 235, 244, 254, 255, 264, 270, 272, 273, 274, 281, 286, 289, 290, 296, 301, 309,312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and(ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, orII. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises(i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 24, 123, and 256 according to the numbering of SEQ ID NO: 39 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 39, or(ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 10, 19, 30, 38, 59, 60, 67, 97, 103, 129, 143, 167, 168, 184, 225, 228, 235, 244, 258, 261, and 298 according to the numbering of SEQ ID NO: 38 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 38, or(iii) an amino acid sequence which is at least 60% identical to SEQ ID NO: 40, or(iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 30, 81 , 93, 95, 118, 138, 139, 200, 202, 210, 260, 283, 288, 294, and 295 according to the numbering of SEQ ID NO: 40 and an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 40, c. the cellulase is selected fromI. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 42, orII. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 46, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 44, or SEQ ID NO: 47, and wherein at least one enzyme is selected from the group consisting of aa. a protease variant of a parent protease, wherein the protease variant comprises(i) an amino acid sequence comprising compared to SEQ ID NO: 16 at least two additional negative charges in the loop region of residues 98 to 104 according to the numbering of SEQ ID NO: 17, and(ii) an amino acid sequence which is at least 60%, but less than 100% identical to SEQ ID NO: 16-34, preferably SEQ ID NO: 16, bb. a mannanase variant of a parent mannanase, wherein the mannanase variant comprises(i) one or more amino acid substitution selected from the group consisting of 86, 89, 96, 101 , 103, 107, 108, 109, 112, 119, 122, 124, 126, 127, 129, 231 , 233,235, 244, 254, 255, 264, 270, 272, 273, 274, 281 , 286, 289, 290, 296, 301 , 309, 312, 314, 317, 319, 341 , 346, 348, 349, 352, 356, and 379 according to the numbering of SEQ ID NO: 35, and(ii) an amino acid sequence which is at least 60%, but less than 100% identical to a sequence according to positions 31-490 of SEQ ID NO: 35, and cc. a cellulase variant comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 42.

2. The composition according to claim 1 , wherein the protease variant has at least 80%, but less than 100% sequence identity with SEQ ID NO: 16 and comprises an amino acid substitution at position 101 , preferably X101 E, according to the numbering of SEQ ID NO: 17.

3. The composition according to claim 1 or claim 2, wherein the mannanase variant has at least 80%, but less than 100% sequence identity with SEQ ID NO: 35 and comprises one or more amino acid substitution selected from the group consisting of X86N, X89V / L, X96D, X101T / V, X103Y / E / A, X107N, X108G, X109Q / A, X112N, X119Y / H / T, X122S, X124E / C / D, X126E, X127A, X129M / L / F, X231Q / K / L / P / Y, X233V, X235H / R / L / Q / N / Y, X244I / V / N, X254W, X255Y / H / R, X264QA / , X270T, X272I, X273T, X274E / C / Q, X281 L, X286E / L / Q / A, X289F / M / H, X290A, X296H / F / Y, X301 E / C / T, X309L, X312F / Y, X314P, X317T, X319D / E, X341 F, X346T, X348S / R / N / M / G, X349T / S / G / D, X352N / G, X356YA / / T / Q / H / C, and X379V, preferably selected from X31V, X89V, X96D, X119Y / H / T, X264Q / V, X289F / M / H, X312F / Y, X348S / R / N / M / G, X349T / S / D / G, X352N / G, and X379V according to the numbering of SEQ ID NO: 35.

4. The composition according to any of the preceding claims, wherein the cellulase variant comprises an amino acid sequence which is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or 100% identical to SEQ ID NO: 42.

5. The composition according to any of the preceding claims, wherein the composition further comprises an amylase, preferably selected from a) an amylase variant of a parent amylase, wherein said amylase variant(i) comprises an amino acid substitution at position 25 according to the numbering of SEQ ID NO: 2,(ii) comprises an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 4, 116, 176, 181 , 186, 195, 206, 225, 251 , 320, 405, and 482 according to the numbering of SEQ ID NO: 2, and(iii) has at least 60%, preferably at least 91% identity, but less than 100% sequence identity with any of SEQ ID NO: 1-15, preferably SEQ ID NO: 1 , and b) an amylase variant of a parent amylase, wherein said amylase variant comprises(i) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 183, 243, 266 and 475 according to the numbering of SEQ ID NO: 9 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 9, or(ii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 38, 126, 129, 153, 180, 187, 199, 203, 241, 362, 377, 458, 459, 460, 476 and 477 according to the numbering of SEQ ID NO: 7 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 7, or(iii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 7, 51, 52, 54, 109, 140, 195, 206, 243, 260, 280, 284, 304, 391, 476 and 477 according to the numbering of SEQ ID NO: 3 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 3, or(iv) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 458 and 471 according to the numbering of SEQ ID NO: 13 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 13, or(v) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 149, 167, 172, 174, 182, 195, 202, 206, 246, 257, 295, 299, 320, 339, 345, 391 , 458, 471 , 473 and 476 according to the numbering of SEQ ID NO: 15 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 15, or(vi) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 9, 118, 149, 182, 186, 195, 202, 246, 257, 295, 299, 320, 323, 339, 345, 405, 421 ,422,428, 458 and 471 according to the numbering of SEQ ID NO: 4 and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO: 4, or(vii) an amino acid substitution at one or more amino acid positions corresponding to amino acid positions selected from the group consisting of 1 , 54, 56, 72, 109, 113, 116, 120, 134, 140, 167, 169, 172, 173, 174, 182, 183, 184, 195, 202, 206,246, 255, 257, 260, 265, 295, 299, 304, 320, 339, 345, 391 , 395, 410, 422, 429, 444, 451 , 458, 473, 474 and 476 according to the numbering of SEQ ID NO: 5; and an amino acid sequence which has at least 60%, but less than 100% sequence identity to SEQ ID NO:

5. The composition according to claim 5, wherein the amylase variant has at least 80%, but less than 100% sequence identity with SEQ ID NO: 1 and the amino acid substitution X25H and one or more amino acid substitutions selected from the group consisting of X4Q, X116K, X176K, X181T, X186E, X195F, X206Y, X225A, X251 E, X320K, X405M, and X482W according to the numbering of SEQ ID NO:

2. The composition according to any of the preceding claims, wherein the composition comprises one or more additional enzymes selected from the group consisting of lipases, hemicellulases, xylanases, DNases, dispersins, pectinases, oxidoreductases, cutinases, phosphodiesterases, licheninases, xanthan-lyases, and hexosaminidases, preferably a lipase. The composition according to any of the preceding claims, wherein the composition is a detergent composition, preferably a laundry detergent composition or a hard surface cleaning detergent composition. The composition according to claim 8, wherein the detergent composition comprises a detergent component selected from the group consisting of enzyme stabilizing system, surfactant, defoamer, builder, polymer, bleaching system (bleach), rheology modifier, hydrotrope, softening agent, desiccant, whitening agent, buffer, suds suppressors, preservative, anticorrosion additive, dyestuff and fragrance. The composition according to any of the preceding claims, wherein the combination of at least two enzymes selected from protease, mannanase, and cellulase in the enzyme composition provides a synergistic cleaning effect. Method of making a composition according to any of claims 1-10 comprising the step of mixing at least two enzyme selected from protease, mannanase, and cellulase. Method for cleaning comprising the step of contacting a textile or a hard surface with a composition according to any of claims 1-10, preferably at low temperature. The method according to claim 12, wherein the method for cleaning is for cleaning a complex stain from a textile or a hard surface.Use of a composition according to any of claims 1-10 for providing a synergistic cleaning effect, preferably at low temperature. Use of a composition according to any of claims 1-10 for removal of a complex stains, preferably at low temperature.

Images